NEW YORK GENOME CENTER INC: Form 990, tax year 2019

View the entire original 990 at ProPublica ↗

Organization: NEW YORK GENOME CENTER INC (EIN 80-0631734)
Tax period: 2019-01-01 to 2019-12-31
Filed: 2020-11-13
IRS object ID: 202013189349305331
Schema version: 2019v5.1
Source: Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header
Form 990
Schedule A
Schedule B
Schedule C
Schedule D
Schedule F
Schedule G
Schedule I
Schedule J
Schedule L
Schedule O

Return header ReturnHeader

Field	Value	IRS element (for citing)
Return	2020-11-13T10:49:09-06:00	ReturnTs
Tax Period End	2019-12-31	TaxPeriodEndDt

Preparer Firm PreparerFirmGrp

Preparer Firm Name PreparerFirmName

Field	Value	IRS element (for citing)
Business Name Line1	KPMG LLP	BusinessNameLine1Txt

Preparer US Address PreparerUSAddress

Field	Value	IRS element (for citing)
Address Line1	345 Park Avenue	AddressLine1Txt
City	New York	CityNm
State Abbreviation	NY	StateAbbreviationCd
ZIP	101540102	ZIPCd

Field	Value	IRS element (for citing)
Return Type	990	ReturnTypeCd
Tax Period Begin	2019-01-01	TaxPeriodBeginDt

Filer Filer

Field	Value	IRS element (for citing)
EIN	800631734	EIN

Business Name BusinessName

Field	Value	IRS element (for citing)
Business Name Line1	NEW YORK GENOME CENTER INC	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
In Care Of	% NANCY KONG	InCareOfNm
Business Name Control	NEWY	BusinessNameControlTxt
Phone	6469777000	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	101 AVENUE OF THE AMERICAS Suite 7T	AddressLine1Txt
City	NEW YORK	CityNm
State Abbreviation	NY	StateAbbreviationCd
ZIP	10013	ZIPCd

Business Officer BusinessOfficerGrp

Field	Value	IRS element (for citing)
Person	NANCY KONG	PersonNm
Person Title	DIRECTOR, FINANCE	PersonTitleTxt
Phone	6469777154	PhoneNum
Signature	2020-11-12	SignatureDt
Discuss With Paid Preparer	Yes (true)	DiscussWithPaidPreparerInd

Preparer Person PreparerPersonGrp

Field	Value	IRS element (for citing)
Preparer Person	DEVIN L DUNCAN	PreparerPersonNm
PTIN	P01249521	PTIN
Phone	2127589700	PhoneNum
Preparation	2020-11-11	PreparationDt

Filing Security Information FilingSecurityInformation

IP Address IPAddress

Field	Value	IRS element (for citing)
I Pv4 Address	127.0.0.1	IPv4AddressTxt

Field	Value	IRS element (for citing)
Federal Original Submission Id	13407320203185000052	FederalOriginalSubmissionId
Federal Original Submission Id	2020-11-13	FederalOriginalSubmissionIdDt
Filing License Type	P	FilingLicenseTypeCd
At Submission Creation Device Id	7426E5478AC3C3B4DF62CAE99E06782BCAD2EE51	AtSubmissionCreationDeviceId
At Submission Filing Device Id	9A787ECE391EA6D2706409A91BA1BFFEBAFC1C1E	AtSubmissionFilingDeviceId

Field	Value	IRS element (for citing)
Tax	2019	TaxYr
Build TS	2021-01-29 14:40:06Z	BuildTS

Form 990 IRS990

Field	Value	IRS element (for citing)
Principal Officer	TOM MANIATIS	PrincipalOfficerNm

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	101 AVENUE OF THE AMERICAS	AddressLine1Txt
City	NEW YORK	CityNm
State Abbreviation	NY	StateAbbreviationCd
ZIP	10013	ZIPCd

Field	Value	IRS element (for citing)
Gross Receipts	$45,525,304	GrossReceiptsAmt
Group Return For Affiliates	false	GroupReturnForAffiliatesInd
Organization501c3	Yes (X)	Organization501c3Ind
Website Address	www.nygenome.org	WebsiteAddressTxt
Type Of Organization Corp	Yes (X)	TypeOfOrganizationCorpInd
Formation	2010	FormationYr
Legal Domicile State	DE	LegalDomicileStateCd
Activity Or Mission	NEW YORK GENOME CENTER (NYGC) IS AN INDEPENDENT, NONPROFIT ACADEMIC RESEARCH INSTITUTION DEDICATED TO GENOMIC DISCOVERY TO ADVANCE HUMAN HEALTH.	ActivityOrMissionDesc
Voting Members Governing Body	25	VotingMembersGoverningBodyCnt
Voting Members Independent	23	VotingMembersIndependentCnt
Total Employee	216	TotalEmployeeCnt
Total Volunteers	23	TotalVolunteersCnt
Total Gross UBI	$1,967,480	TotalGrossUBIAmt
Net Unrelated Bus Txbl Incm	-$609,504	NetUnrelatedBusTxblIncmAmt
PY Contributions Grants	$115,038,771	PYContributionsGrantsAmt
CY Contributions Grants	$32,878,926	CYContributionsGrantsAmt
PY Program Service Revenue	$13,156,320	PYProgramServiceRevenueAmt
CY Program Service Revenue	$9,402,354	CYProgramServiceRevenueAmt
PY Investment Income	-$14,680	PYInvestmentIncomeAmt
CY Investment Income	$174,909	CYInvestmentIncomeAmt
PY Other Revenue	$268,539	PYOtherRevenueAmt
CY Other Revenue	-$211,744	CYOtherRevenueAmt
PY Total Revenue	$128,448,950	PYTotalRevenueAmt
CY Total Revenue	$42,244,445	CYTotalRevenueAmt
PY Grants And Similar Paid	$1,300,475	PYGrantsAndSimilarPaidAmt
CY Grants And Similar Paid	$1,899,777	CYGrantsAndSimilarPaidAmt
PY Benefits Paid To Members	$0	PYBenefitsPaidToMembersAmt
CY Benefits Paid To Members	$0	CYBenefitsPaidToMembersAmt
PY Salaries Comp Emp Bnft Paid	$28,154,290	PYSalariesCompEmpBnftPaidAmt
CY Salaries Comp Emp Bnft Paid	$28,935,750	CYSalariesCompEmpBnftPaidAmt
PY Total Prof Fndrsng Expns	$58,590	PYTotalProfFndrsngExpnsAmt
CY Total Prof Fndrsng Expns	$129,829	CYTotalProfFndrsngExpnsAmt
CY Total Fundraising Expense	$1,124,071	CYTotalFundraisingExpenseAmt
PY Other Expenses	$55,044,830	PYOtherExpensesAmt
CY Other Expenses	$49,234,412	CYOtherExpensesAmt
PY Total Expenses	$84,558,185	PYTotalExpensesAmt
CY Total Expenses	$80,199,768	CYTotalExpensesAmt
PY Revenues Less Expenses	$43,890,765	PYRevenuesLessExpensesAmt
CY Revenues Less Expenses	-$37,955,323	CYRevenuesLessExpensesAmt
Total Assets BOY	$148,772,470	TotalAssetsBOYAmt
Total Assets EOY	$97,126,046	TotalAssetsEOYAmt
Total Liabilities BOY	$63,342,890	TotalLiabilitiesBOYAmt
Total Liabilities EOY	$49,651,789	TotalLiabilitiesEOYAmt
Net Assets Or Fund Balances BOY	$85,429,580	NetAssetsOrFundBalancesBOYAmt
Net Assets Or Fund Balances EOY	$47,474,257	NetAssetsOrFundBalancesEOYAmt
Info In Schedule O Part III	Yes (X)	InfoInScheduleOPartIIIInd
Mission	OPERATE A STATE-OF-THE-ART, WORLD-CLASS GENOMIC RESEARCH CENTER THAT CREATES AND USES ADVANCED GENOMICS TO UNDERSTAND THE GENETIC BASIS OF DISEASE. FOR MORE INFORMATION, SEE SCHEDULE O.	MissionDesc
Significant New Program Srvc	false	SignificantNewProgramSrvcInd
Significant Change	false	SignificantChangeInd
Expense	$60,802,228	ExpenseAmt
Grant	$1,899,777	GrantAmt
Revenue	$8,140,024	RevenueAmt
Desc	RESEARCH AND RESEARCH SEQUENCING - NYGC'S RESEARCH SCIENTISTS AND FACULTY ARE EXPLORING GENOMIC CONTRIBUTORS TO HUMAN DISEASE, BOTH IN THEIR OWN PROJECTS AND THROUGH COLLABORATIONS. NYGC RESEARCHERS HAVE PROJECTS UNDERWAY IN CANCER, INCLUDING LUNG, LIVER, BREAST AND MELANOMA, A MULTI-SITE VERY RARE CANCER PROJECT AND A LARGE COLLABORATIVE PROJECT STUDYING CANCER IN UNDERSERVED POPULATIONS IN NYC; NEURODEGENERATIVE DISEASES, INCLUDING ALS AND DEMENTIA; AND NEUROPSYCHIATRIC DISEASES, FOCUSING ON AUTISM, AMONG OTHERS. FOR MORE INFORMATION SEE SCHEDULE O.	Desc

Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp

Field	Value	IRS element (for citing)
Expense	$3,801,044	ExpenseAmt
Revenue	$1,262,330	RevenueAmt
Desc	CLINICAL SEQUENCING - NYGC IS AUTHORIZED BY THE NEW YORK STATE DEPARTMENT OF HEALTH TO OFFER THE FOLLOWING APPROVED CLINICAL TESTS THROUGH ITS CLEP/CLIA-CERTIFIED CLINICAL LABORATORY: CONSTITUTIONAL WHOLE GENOME SEQUENCING FOR UNDIAGNOSED DISEASE, CONSTITUTIONAL WHOLE GENOME SEQUENCING FOR PREDISPOSITIONAL GENETIC SCREENING, ONCOLOGY WHOLE GENOME AND TRANSCRIPTOME SEQUENCING, CONSTITUTIONAL WHOLE EXOME SEQUENCING, TARGETED VARIANT TESTING USING SANGER SEQUENCING, SMASH GENOMIC ASSAY, OFF-SITE MSK-IMPACT SEQUENCING, AND SEQUENCING OF PREPARED LIBRARIES FOR MGTL.	Desc

Field	Value	IRS element (for citing)
Total Program Service Expenses	$64,603,272	TotalProgramServiceExpensesAmt
Described In Section501c3	Yes (true)	DescribedInSection501c3Ind
Schedule B Required	Yes (true)	ScheduleBRequiredInd
Political Campaign Acty	false	PoliticalCampaignActyInd
Lobbying Activities	Yes (true)	LobbyingActivitiesInd
Subject To Proxy Tax	false	SubjectToProxyTaxInd
Donor Advised Fund	false	DonorAdvisedFundInd
Conservation Easements	false	ConservationEasementsInd
Collections Of Art	false	CollectionsOfArtInd
Credit Counseling	false	CreditCounselingInd
Donor Rstr Or Quasi Endowments	false	DonorRstrOrQuasiEndowmentsInd
Report Land Building Equipment	Yes (true)	ReportLandBuildingEquipmentInd
Report Investments Other Sec	false	ReportInvestmentsOtherSecInd
Report Program Related Invst	false	ReportProgramRelatedInvstInd
Report Other Assets	Yes (true)	ReportOtherAssetsInd
Report Other Liabilities	Yes (true)	ReportOtherLiabilitiesInd
Include FIN48 Footnote	Yes (true)	IncludeFIN48FootnoteInd
Independent Audit Fincl Stmt	Yes (true)	IndependentAuditFinclStmtInd
Consolidated Audit Fincl Stmt	false	ConsolidatedAuditFinclStmtInd
School Operating	false	SchoolOperatingInd
Foreign Office	Yes (true)	ForeignOfficeInd
Foreign Activities	Yes (true)	ForeignActivitiesInd
More Than5000 K To Org	Yes (true)	MoreThan5000KToOrgInd
More Than5000 K To Individuals	false	MoreThan5000KToIndividualsInd
Professional Fundraising	Yes (true)	ProfessionalFundraisingInd
Fundraising Activities	false	FundraisingActivitiesInd
Gaming Activities	false	GamingActivitiesInd
Operate Hospital	false	OperateHospitalInd
Grants To Organizations	Yes (true)	GrantsToOrganizationsInd
Grants To Individuals	false	GrantsToIndividualsInd
Schedule J Required	Yes (true)	ScheduleJRequiredInd
Tax Exempt Bonds	false	TaxExemptBondsInd
Engaged In Excess Benefit Trans	false	EngagedInExcessBenefitTransInd
PY Excess Benefit Trans	false	PYExcessBenefitTransInd
Loan Outstanding	false	LoanOutstandingInd
Grant To Related Person	false	GrantToRelatedPersonInd
Business Rln With Org Mem	false	BusinessRlnWithOrgMemInd
Business Rln With Fam Mem	Yes (true)	BusinessRlnWithFamMemInd
Business Rln With35 Ctrl Ent	false	BusinessRlnWith35CtrlEntInd
Deductible Non Cash Contri	false	DeductibleNonCashContriInd
Deductible Art Contribution	false	DeductibleArtContributionInd
Terminate Operations	false	TerminateOperationsInd
Partial Liquidation	false	PartialLiquidationInd
Disregarded Entity	false	DisregardedEntityInd
Related Entity	false	RelatedEntityInd
Related Organization Ctrl Ent	false	RelatedOrganizationCtrlEntInd
Trnsfr Exmpt Non Chrtbl Rltd Org	false	TrnsfrExmptNonChrtblRltdOrgInd
Activities Conducted Prtshp	false	ActivitiesConductedPrtshpInd
Schedule O Required	Yes (true)	ScheduleORequiredInd
IRP Document	70	IRPDocumentCnt
IRP Document W2 G	0	IRPDocumentW2GCnt
Backup Wthld Compliance	Yes (true)	BackupWthldComplianceInd
Employee	216	EmployeeCnt
Employment Tax Returns Filed	Yes (true)	EmploymentTaxReturnsFiledInd
Unrelated Bus Incm Over Limit	Yes (true)	UnrelatedBusIncmOverLimitInd
Form990 T Filed	Yes (true)	Form990TFiledInd
Foreign Financial Account	false	ForeignFinancialAccountInd
Prohibited Tax Shelter Trans	false	ProhibitedTaxShelterTransInd
Taxable Party Notification	false	TaxablePartyNotificationInd
Nondeductible Contributions	false	NondeductibleContributionsInd
Quid Pro Quo Contributions	false	QuidProQuoContributionsInd
Form8282 Property Disposed Of	false	Form8282PropertyDisposedOfInd
Rcv Fnds To Pay Prsnl Bnft Cntrct	false	RcvFndsToPayPrsnlBnftCntrctInd
Pay Premiums Prsnl Bnft Cntrct	false	PayPremiumsPrsnlBnftCntrctInd
Indoor Tanning Services	false	IndoorTanningServicesInd
Subj To Tax Rmnrtn Ex Prcht Pymt	Yes (true)	SubjToTaxRmnrtnExPrchtPymtInd
Subject To Excs Tax Net Invst Inc	false	SubjectToExcsTaxNetInvstIncInd
Info In Schedule O Part VI	Yes (X)	InfoInScheduleOPartVIInd
Governing Body Voting Members	25	GoverningBodyVotingMembersCnt
Independent Voting Member	23	IndependentVotingMemberCnt
Family Or Business Rln	false	FamilyOrBusinessRlnInd
Delegation Of Mgmt Duties	false	DelegationOfMgmtDutiesInd
Change To Org Documents	false	ChangeToOrgDocumentsInd
Material Diversion Or Misuse	false	MaterialDiversionOrMisuseInd
Members Or Stockholders	Yes (true)	MembersOrStockholdersInd
Election Of Board Members	Yes (true)	ElectionOfBoardMembersInd
Decisions Subject To Approva	false	DecisionsSubjectToApprovaInd
Minutes Of Governing Body	Yes (true)	MinutesOfGoverningBodyInd
Minutes Of Committees	Yes (true)	MinutesOfCommitteesInd
Officer Mailing Address	false	OfficerMailingAddressInd
Local Chapters	false	LocalChaptersInd
Form990 Provided To Gvrn Body	Yes (true)	Form990ProvidedToGvrnBodyInd
Conflict Of Interest Policy	Yes (true)	ConflictOfInterestPolicyInd
Annual Disclosure Covered Prsn	Yes (true)	AnnualDisclosureCoveredPrsnInd
Regular Monitoring Enfrc	Yes (true)	RegularMonitoringEnfrcInd
Whistleblower Policy	Yes (true)	WhistleblowerPolicyInd
Document Retention Policy	Yes (true)	DocumentRetentionPolicyInd
Compensation Process CEO	false	CompensationProcessCEOInd
Compensation Process Other	Yes (true)	CompensationProcessOtherInd
Investment In Joint Venture	false	InvestmentInJointVentureInd
States Where Copy Of Return Is Fld	AL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	AK	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	AR	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	CA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	CO	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	CT	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	FL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	GA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	HI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	IL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	KS	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	KY	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	LA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	ME	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MD	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MN	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MS	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MO	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NH	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NJ	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NM	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NY	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NC	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	ND	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OH	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OK	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OR	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	PA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	RI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	SC	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	TN	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	UT	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	VA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WV	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WI	StatesWhereCopyOfReturnIsFldCd
Upon Request	Yes (X)	UponRequestInd

Books In Care Of Detail BooksInCareOfDetail

Field	Value	IRS element (for citing)
Person	NANCY KONG	PersonNm
Phone	6469777154	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	101 AVENUE OF THE AMERICAS 7TH FLO	AddressLine1Txt
City	NEW YORK	CityNm
State Abbreviation	NY	StateAbbreviationCd
ZIP	10013	ZIPCd

Field	Value	IRS element (for citing)
Info In Schedule O Part VII	Yes (X)	InfoInScheduleOPartVIIInd

Form990 Part VII Section A Form990PartVIISectionAGrp (40 entries)

TitleTitleTxt	Average Hours Per WeekAverageHoursPerWeekRt	Average Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRt	Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd	OfficerOfficerInd	Reportable Comp From OrgReportableCompFromOrgAmt	Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt	Other CompensationOtherCompensationAmt	Key EmployeeKeyEmployeeInd	Highest Compensated EmployeeHighestCompensatedEmployeeInd	Former Ofcr Director TrusteeFormerOfcrDirectorTrusteeInd
CHERYL A MOORE
PRESIDENT & COO	40.0	0.0	Yes (X)	Yes (X)	$1,840,182	$0	$218,228
Tom Maniatis PHD
SCIENTIFIC DIR & CEO	40.0	0.0	Yes (X)	Yes (X)	$582,430	$0	$0
ELIZABETH BROOKS O'BRI
VICE PRESIDENT & GEN. COUNSEL	40.0	0.0		Yes (X)	$419,097	$0	$44,284
CAROL ASHE
CHIEF BUSINESS OFFICER	40.0	0.0			$414,579	$0	$14,117	Yes (X)
KATHLEEN MCGOVERN KEAR
VICE PRESIDENT, DEV'T & COMM	40.0	0.0			$399,020	$0	$27,668	Yes (X)
ANA LUCIA BASTIANI-POS
SVP, Finance and Admin	40.0	0.0			$386,106	$0	$17,268	Yes (X)
SOREN GERMER
SVP, Genome Technologies	40.0	0.0			$308,155	$0	$29,347	Yes (X)
SHAILAJA GARGEYA
SENIOR DIR, SOFTWARE ENGINEER	40.0	0.0			$316,290	$0	$16,877		Yes (X)
TOBY BLOOM
Former Key Employee	40.0	0.0			$301,520	$0	$17,821			Yes (X)
CHARLES GAGNON
SENIOR DIR, IT INFRASTRUCTURE	40.0	0.0			$273,903	$0	$41,224	Yes (X)
DAYNA M OSCHWALD
chief of staff, office sci dir	40.0	0.0			$251,680	$0	$23,511		Yes (X)
CHRISTOPHER PHIFER BLA
DIRECTOR, RESEARCH COMPUTING	40.0	0.0			$206,054	$0	$35,982		Yes (X)
HANNAH GOULDING
Senior Director, HR	40.0	0.0			$213,006	$0	$10,767		Yes (X)
MELISSA PROBER
Senior Associate Counsel	40.0	0.0			$212,663	$0	$9,801		Yes (X)
MICHAEL CHARLES ZODY
Scientific Dir, COMP BIOLOGY	40.0	0.0			$197,824	$0	$15,975	Yes (X)
DAFNA BAR-SAGI PHD
DIRECTOR	1.0	0.0	Yes (X)		$0	$0	$0
RUSSELL L CARSON MBA
DIRECTOR & CO-CHAIR	4.0	0.0	Yes (X)	Yes (X)	$0	$0	$0
ELI CASDIN
DIRECTOR (START 10/31/19)	1.0	0.0	Yes (X)		$0	$0	$0
DENNIS S CHARNEY MD
DIRECTOR	1.0	0.0	Yes (X)		$0	$0	$0
AUGUSTINE MK CHOI M
DIRECTOR	1.0	0.0	Yes (X)		$0	$0	$0
NICHOLAS DONOFRIO
DIRECTOR	1.0	0.0	Yes (X)		$0	$0	$0
JOHN B EHRENKRANZ
DIRECTOR	1.0	0.0	Yes (X)		$0	$0	$0
ANTHONY B EVNIN PHD
DIRECTOR	1.0	0.0	Yes (X)		$0	$0	$0
LEE GOLDMAN MD MPH
DIRECTOR	1.0	0.0	Yes (X)		$0	$0	$0
JOHN HAVENS
DIRECTOR (THROUGH 2/26/19)	1.0	0.0	Yes (X)		$0	$0	$0
WESLIE R JANEWAY
DIRECTOR	1.0	0.0	Yes (X)		$0	$0	$0
KENNETH KAUSHANSKY MD
DIRECTOR (START 10/31/19)	1.0	0.0	Yes (X)		$0	$0	$0
RICHARD P LIFTON MD
DIRECTOR	1.0	0.0	Yes (X)		$0	$0	$0
EDISON T LIU MD
DIRECTOR	1.0	0.0	Yes (X)		$0	$0	$0
HERB PARDES MD
DIRECTOR & VICE CHAIR	1.0	0.0	Yes (X)		$0	$0	$0
FRANK E RICHARDSON M
DIRECTOR	1.0	0.0	Yes (X)		$0	$0	$0
IVAN G SEIDENBERG MB
DIRECTOR & CO-CHAIR	4.0	0.0	Yes (X)	Yes (X)	$0	$0	$0
FRANK V SICA
DIRECTOR / COMMITTEE CHAIR	1.0	0.0	Yes (X)		$0	$0	$0
JIM SIMONS PHD
DIRECTOR	1.0	0.0	Yes (X)		$0	$0	$0
STEVEN D SINGER ESQ
DIRECTOR	1.0	0.0	Yes (X)		$0	$0	$0
SAMUEL L STANLEY JR
DIRECTOR (THROUGH 7/31/19)	1.0	0.0	Yes (X)		$0	$0	$0
BRUCE STILLMAN PHD
DIRECTOR	1.0	0.0	Yes (X)		$0	$0	$0
CRAIG B THOMPSON MD
DIRECTOR	1.0	0.0	Yes (X)		$0	$0	$0
GORDON F TOMASELLI M
DIRECTOR	1.0	0.0	Yes (X)		$0	$0	$0
KEVIN J TRACEY MD
DIRECTOR	1.0	0.0	Yes (X)		$0	$0	$0

Field	Value	IRS element (for citing)
Total Reportable Comp From Org	$6,322,509	TotalReportableCompFromOrgAmt
Tot Reportable Comp Rltd Org	$0	TotReportableCompRltdOrgAmt
Total Other Compensation	$522,870	TotalOtherCompensationAmt
Indiv Rcvd Greater Than100 K	78	IndivRcvdGreaterThan100KCnt
Former Ofcr Employees Listed	Yes (true)	FormerOfcrEmployeesListedInd
Total Comp Greater Than150 K	Yes (true)	TotalCompGreaterThan150KInd
Compensation From Other Srcs	Yes (true)	CompensationFromOtherSrcsInd

Contractor Compensation ContractorCompensationGrp (5 entries)

Address Line1ContractorAddress/USAddress/AddressLine1Txt	CityContractorAddress/USAddress/CityNm	State AbbreviationContractorAddress/USAddress/StateAbbreviationCd	ZIPContractorAddress/USAddress/ZIPCd	ServicesServicesDesc	CompensationCompensationAmt
PJ Mechanical Service Maintenan
55 Broad Street	NEW YORK	NY	10004	Engineering Services	$896,332
Turner Construction Company
375 Hudson Street	NEW YORK	NY	10004	General contractor	$686,787
Guardian Service Industries Inc
88005 EXPEDITE WAY	CHICAGO	IL	60695	CLEANING SERVICES	$411,477
Savant Consulting
47 Howell Road	MOUNTAIN LAKES	NJ	07046	Executive Recruiting	$236,613
Passion 4 People Consulting LLC
47-25 34th Street 4th Floor	LONG ISLAND CITY	NY	11101	Temporary Staffing	$198,025

Field	Value	IRS element (for citing)
Cntrct Rcvd Greater Than100 K	10	CntrctRcvdGreaterThan100KCnt
Membership Dues	$3,135,000	MembershipDuesAmt
Government Grants	$18,990,433	GovernmentGrantsAmt
All Other Contributions	$10,753,493	AllOtherContributionsAmt
Noncash Contributions	$0	NoncashContributionsAmt
Total Contributions	$32,878,926	TotalContributionsAmt

Program Service Revenue ProgramServiceRevenueGrp (2 entries)

DescDesc	BusinessBusinessCd	Total Revenue ColumnTotalRevenueColumnAmt	Related Or Exempt Func IncomeRelatedOrExemptFuncIncomeAmt	Unrelated Business RevenueUnrelatedBusinessRevenueAmt
RESEARCH SEQUENCING	541700	$8,140,024	$6,172,544	$1,967,480
CLINICAL SEQUENCING	541700	$1,262,330	$1,262,330

Field	Value	IRS element (for citing)
Total Program Service Revenue	$9,402,354	TotalProgramServiceRevenueAmt

Investment Income InvestmentIncomeGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$174,909	TotalRevenueColumnAmt
Exclusion	$174,909	ExclusionAmt

Incm From Invest Bond Proceeds IncmFromInvestBondProceedsGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$0	TotalRevenueColumnAmt

Royalties Revenue RoyaltiesRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$636,409	TotalRevenueColumnAmt
Exclusion	$636,409	ExclusionAmt

Gross Rents GrossRentsGrp

Field	Value	IRS element (for citing)
Real	$2,394,657	RealAmt

Less Rental Expenses LessRentalExpensesGrp

Field	Value	IRS element (for citing)
Real	$3,280,859	RealAmt

Rental Income Or Loss RentalIncomeOrLossGrp

Field	Value	IRS element (for citing)
Real	-$886,202	RealAmt
Personal	$0	PersonalAmt

Net Rental Income Or Loss NetRentalIncomeOrLossGrp

Field	Value	IRS element (for citing)
Total Revenue Column	-$886,202	TotalRevenueColumnAmt
Exclusion	-$886,202	ExclusionAmt

Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$0	TotalRevenueColumnAmt

Field	Value	IRS element (for citing)
Fundraising Gross Income	$0	FundraisingGrossIncomeAmt
Fundraising Direct Expenses	$0	FundraisingDirectExpensesAmt

Net Incm From Fundraising Evt NetIncmFromFundraisingEvtGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$0	TotalRevenueColumnAmt

Field	Value	IRS element (for citing)
Gaming Gross Income	$0	GamingGrossIncomeAmt
Gaming Direct Expenses	$0	GamingDirectExpensesAmt

Net Income From Gaming NetIncomeFromGamingGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$0	TotalRevenueColumnAmt

Field	Value	IRS element (for citing)
Gross Sales Of Inventory	$0	GrossSalesOfInventoryAmt
Cost Of Goods Sold	$0	CostOfGoodsSoldAmt

Net Income Or Loss NetIncomeOrLossGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$0	TotalRevenueColumnAmt

Other Revenue Misc OtherRevenueMiscGrp (2 entries)

DescDesc	BusinessBusinessCd	Total Revenue ColumnTotalRevenueColumnAmt	ExclusionExclusionAmt
EVENT SPACE REVENUE	900099	$29,800	$29,800
OTHER REVENUE	900099	$8,249	$8,249

Field	Value	IRS element (for citing)
Other Revenue Total	$38,049	OtherRevenueTotalAmt

Total Revenue TotalRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$42,244,445	TotalRevenueColumnAmt
Related Or Exempt Func Income	$7,434,874	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$1,967,480	UnrelatedBusinessRevenueAmt
Exclusion	-$36,835	ExclusionAmt

Grants To Domestic Orgs GrantsToDomesticOrgsGrp

Field	Value	IRS element (for citing)
Total	$1,762,476	TotalAmt
Program Services	$1,762,476	ProgramServicesAmt

Grants To Domestic Individuals GrantsToDomesticIndividualsGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Foreign Grants ForeignGrantsGrp

Field	Value	IRS element (for citing)
Total	$137,301	TotalAmt
Program Services	$137,301	ProgramServicesAmt

Benefits To Members BenefitsToMembersGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp

Field	Value	IRS element (for citing)
Total	$6,845,379	TotalAmt
Program Services	$2,303,466	ProgramServicesAmt
Management And General	$4,115,224	ManagementAndGeneralAmt
Fundraising	$426,689	FundraisingAmt

Comp Disqual Persons CompDisqualPersonsGrp

Field	Value	IRS element (for citing)
Total	$135,071	TotalAmt
Program Services	$135,071	ProgramServicesAmt

Other Salaries And Wages OtherSalariesAndWagesGrp

Field	Value	IRS element (for citing)
Total	$16,738,434	TotalAmt
Program Services	$12,674,995	ProgramServicesAmt
Management And General	$3,851,744	ManagementAndGeneralAmt
Fundraising	$211,695	FundraisingAmt

Pension Plan Contributions PensionPlanContributionsGrp

Field	Value	IRS element (for citing)
Total	$1,005,299	TotalAmt
Program Services	$684,911	ProgramServicesAmt
Management And General	$300,550	ManagementAndGeneralAmt
Fundraising	$19,838	FundraisingAmt

Other Employee Benefits OtherEmployeeBenefitsGrp

Field	Value	IRS element (for citing)
Total	$2,466,292	TotalAmt
Program Services	$1,536,505	ProgramServicesAmt
Management And General	$907,777	ManagementAndGeneralAmt
Fundraising	$22,010	FundraisingAmt

Payroll Taxes PayrollTaxesGrp

Field	Value	IRS element (for citing)
Total	$1,745,275	TotalAmt
Program Services	$1,277,011	ProgramServicesAmt
Management And General	$432,710	ManagementAndGeneralAmt
Fundraising	$35,554	FundraisingAmt

Fees For Services Management FeesForServicesManagementGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Fees For Services Legal FeesForServicesLegalGrp

Field	Value	IRS element (for citing)
Total	$333,165	TotalAmt
Management And General	$333,165	ManagementAndGeneralAmt

Fees For Services Accounting FeesForServicesAccountingGrp

Field	Value	IRS element (for citing)
Total	$137,269	TotalAmt
Management And General	$137,269	ManagementAndGeneralAmt

Fees For Services Lobbying FeesForServicesLobbyingGrp

Field	Value	IRS element (for citing)
Total	$45,250	TotalAmt
Fundraising	$45,250	FundraisingAmt

Fees For Services Prof Fundraising FeesForServicesProfFundraising

Field	Value	IRS element (for citing)
Total	$129,829	TotalAmt
Fundraising	$129,829	FundraisingAmt

Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Fees For Services Other FeesForServicesOtherGrp

Field	Value	IRS element (for citing)
Total	$2,271,464	TotalAmt
Program Services	$1,884,934	ProgramServicesAmt
Management And General	$386,530	ManagementAndGeneralAmt

Advertising AdvertisingGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Office Expenses OfficeExpensesGrp

Field	Value	IRS element (for citing)
Total	$515,783	TotalAmt
Program Services	$139,845	ProgramServicesAmt
Management And General	$374,710	ManagementAndGeneralAmt
Fundraising	$1,228	FundraisingAmt

Information Technology InformationTechnologyGrp

Field	Value	IRS element (for citing)
Total	$2,405,819	TotalAmt
Program Services	$2,157,843	ProgramServicesAmt
Management And General	$247,976	ManagementAndGeneralAmt

Royalties RoyaltiesGrp

Field	Value	IRS element (for citing)
Total	$224,718	TotalAmt
Program Services	$224,718	ProgramServicesAmt

Occupancy OccupancyGrp

Field	Value	IRS element (for citing)
Total	$13,114,006	TotalAmt
Program Services	$11,406,849	ProgramServicesAmt
Management And General	$1,550,910	ManagementAndGeneralAmt
Fundraising	$156,247	FundraisingAmt

Travel TravelGrp

Field	Value	IRS element (for citing)
Total	$319,657	TotalAmt
Program Services	$246,721	ProgramServicesAmt
Management And General	$67,529	ManagementAndGeneralAmt
Fundraising	$5,407	FundraisingAmt

Pymt Travel Entrtnmnt Pub Ofcl PymtTravelEntrtnmntPubOfclGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Conferences Meetings ConferencesMeetingsGrp

Field	Value	IRS element (for citing)
Total	$316,374	TotalAmt
Program Services	$137,225	ProgramServicesAmt
Management And General	$167,740	ManagementAndGeneralAmt
Fundraising	$11,409	FundraisingAmt

Interest InterestGrp

Field	Value	IRS element (for citing)
Total	$841,753	TotalAmt
Program Services	$635,620	ProgramServicesAmt
Management And General	$197,279	ManagementAndGeneralAmt
Fundraising	$8,854	FundraisingAmt

Payments To Affiliates PaymentsToAffiliatesGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Depreciation Depletion DepreciationDepletionGrp

Field	Value	IRS element (for citing)
Total	$9,680,141	TotalAmt
Program Services	$8,985,905	ProgramServicesAmt
Management And General	$649,624	ManagementAndGeneralAmt
Fundraising	$44,612	FundraisingAmt

Insurance InsuranceGrp

Field	Value	IRS element (for citing)
Total	$461,374	TotalAmt
Management And General	$461,374	ManagementAndGeneralAmt

Other Expenses OtherExpensesGrp (4 entries)

DescDesc	TotalTotalAmt	Program ServicesProgramServicesAmt	Management And GeneralManagementAndGeneralAmt	FundraisingFundraisingAmt
DIRECT COST OF SEQUENCING	$15,467,596	$15,467,596
RESEARCH & CLIA	$2,316,257	$2,316,257
RECRUITMENT	$381,455	$336,006	$45,449
ALL OTHER EXPENSE	$402,331	$152,017	$244,865	$5,449

Total Functional Expenses TotalFunctionalExpensesGrp

Field	Value	IRS element (for citing)
Total	$80,199,768	TotalAmt
Program Services	$64,603,272	ProgramServicesAmt
Management And General	$14,472,425	ManagementAndGeneralAmt
Fundraising	$1,124,071	FundraisingAmt

Cash Non Interest Bearing CashNonInterestBearingGrp

Field	Value	IRS element (for citing)
BOY	$7,834,528	BOYAmt
EOY	$11,828,949	EOYAmt

Savings And Temp Cash Invst SavingsAndTempCashInvstGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Pledges And Grants Receivable PledgesAndGrantsReceivableGrp

Field	Value	IRS element (for citing)
BOY	$51,450,236	BOYAmt
EOY	$6,037,230	EOYAmt

Accounts Receivable AccountsReceivableGrp

Field	Value	IRS element (for citing)
BOY	$7,070,357	BOYAmt
EOY	$5,125,099	EOYAmt

Receivables From Officers Etc ReceivablesFromOfficersEtcGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Rcvbl From Disqualified Prsn RcvblFromDisqualifiedPrsnGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Oth Notes Loans Receivable Net OthNotesLoansReceivableNetGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Inventories For Sale Or Use InventoriesForSaleOrUseGrp

Field	Value	IRS element (for citing)
BOY	$3,402,687	BOYAmt
EOY	$2,964,323	EOYAmt

Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp

Field	Value	IRS element (for citing)
BOY	$3,120,795	BOYAmt
EOY	$3,956,650	EOYAmt

Field	Value	IRS element (for citing)
Land Bldg Equip Cost Or Other Bss	$129,908,990	LandBldgEquipCostOrOtherBssAmt
Land Bldg Equip Accum Deprec	$72,237,589	LandBldgEquipAccumDeprecAmt

Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp

Field	Value	IRS element (for citing)
BOY	$65,127,906	BOYAmt
EOY	$57,671,401	EOYAmt

Investments Pub Traded Sec InvestmentsPubTradedSecGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Investments Other Securities InvestmentsOtherSecuritiesGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Investments Program Related InvestmentsProgramRelatedGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Intangible Assets IntangibleAssetsGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Other Assets Total OtherAssetsTotalGrp

Field	Value	IRS element (for citing)
BOY	$10,765,961	BOYAmt
EOY	$9,542,394	EOYAmt

Total Assets TotalAssetsGrp

Field	Value	IRS element (for citing)
BOY	$148,772,470	BOYAmt
EOY	$97,126,046	EOYAmt

Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp

Field	Value	IRS element (for citing)
BOY	$11,850,899	BOYAmt
EOY	$6,109,365	EOYAmt

Grants Payable GrantsPayableGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Deferred Revenue DeferredRevenueGrp

Field	Value	IRS element (for citing)
BOY	$5,322,019	BOYAmt
EOY	$10,610,221	EOYAmt

Tax Exempt Bond Liabilities TaxExemptBondLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Escrow Account Liability EscrowAccountLiabilityGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Loans From Officers Directors LoansFromOfficersDirectorsGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Mortg Notes Pybl Scrd Invst Prop MortgNotesPyblScrdInvstPropGrp

Field	Value	IRS element (for citing)
BOY	$4,757,610	BOYAmt
EOY	$2,144,347	EOYAmt

Unsecured Notes Loans Payable UnsecuredNotesLoansPayableGrp

Field	Value	IRS element (for citing)
BOY	$14,569,000	BOYAmt
EOY	$4,820,000	EOYAmt

Other Liabilities OtherLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$26,843,362	BOYAmt
EOY	$25,967,856	EOYAmt

Total Liabilities TotalLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$63,342,890	BOYAmt
EOY	$49,651,789	EOYAmt

Field	Value	IRS element (for citing)
Organization Follows FASB117	Yes (X)	OrganizationFollowsFASB117Ind

No Donor Restriction Net Assets NoDonorRestrictionNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$33,045,706	BOYAmt
EOY	$40,350,629	EOYAmt

Donor Restriction Net Assets DonorRestrictionNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$52,383,874	BOYAmt
EOY	$7,123,628	EOYAmt

Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$85,429,580	BOYAmt
EOY	$47,474,257	EOYAmt

Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$148,772,470	BOYAmt
EOY	$97,126,046	EOYAmt

Field	Value	IRS element (for citing)
Reconcilation Revenue Expnss	-$37,955,323	ReconcilationRevenueExpnssAmt
Method Of Accounting Accrual	Yes (X)	MethodOfAccountingAccrualInd
Accountant Compile Or Review	false	AccountantCompileOrReviewInd
FS Audited	Yes (true)	FSAuditedInd

FS Audited Basis FSAuditedBasisGrp

Field	Value	IRS element (for citing)
Separate Basis Fincl Stmt	Yes (X)	SeparateBasisFinclStmtInd

Field	Value	IRS element (for citing)
Audit Committee	Yes (true)	AuditCommitteeInd
Federal Grant Audit Required	Yes (true)	FederalGrantAuditRequiredInd
Federal Grant Audit Performed	Yes (true)	FederalGrantAuditPerformedInd

Schedule A IRS990ScheduleA

Field	Value	IRS element (for citing)
Public Organization170	Yes (X)	PublicOrganization170Ind

Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$61,060,764	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$94,901,046	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$70,723,214	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$115,038,771	CurrentTaxYearMinus1YearAmt
Current Tax Year	$32,878,926	CurrentTaxYearAmt
Total	$374,602,721	TotalAmt

Tax Rev Levied Orgnztnl Bnft170 TaxRevLeviedOrgnztnlBnft170Grp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Govt Furn Srvc Fclts Vl170 GovtFurnSrvcFcltsVl170Grp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Total Calendar Year170 TotalCalendarYear170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$61,060,764	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$94,901,046	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$70,723,214	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$115,038,771	CurrentTaxYearMinus1YearAmt
Current Tax Year	$32,878,926	CurrentTaxYearAmt
Total	$374,602,721	TotalAmt

Field	Value	IRS element (for citing)
Substantial Contributors Tot	$160,330,929	SubstantialContributorsTotAmt
Public Support Total170	$214,271,792	PublicSupportTotal170Amt

Gross Investment Income170 GrossInvestmentIncome170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$268,801	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$302,728	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$378,725	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$2,090,669	CurrentTaxYearMinus1YearAmt
Current Tax Year	$3,205,975	CurrentTaxYearAmt
Total	$6,246,898	TotalAmt

Unrelated Business Net Incm170 UnrelatedBusinessNetIncm170Grp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Other Income170 OtherIncome170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$116,870	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$58,024	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$95,299	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$104,653	CurrentTaxYearMinus1YearAmt
Current Tax Year	$38,049	CurrentTaxYearAmt
Total	$412,895	TotalAmt

Field	Value	IRS element (for citing)
Total Support	$381,262,514	TotalSupportAmt
Gross Receipts Rltd Activities	$101,155,177	GrossReceiptsRltdActivitiesAmt
Public Support CY170	0.56201	PublicSupportCY170Pct
Public Support PY170	0.56486	PublicSupportPY170Pct
Thirty Thr Pct Suprt Tests CY170	Yes (X)	ThirtyThrPctSuprtTestsCY170Ind

Schedule B IRS990ScheduleB

Contributor Information ContributorInformationGrp

Field	Value	IRS element (for citing)
Contributor	RESTRICTED	ContributorNum

Contributor Business Name ContributorBusinessName

Field	Value	IRS element (for citing)
Business Name Line1	RESTRICTED	BusinessNameLine1

Contributor US Address ContributorUSAddress

Field	Value	IRS element (for citing)
Address Line1	RESTRICTED	AddressLine1
Address Line2	RESTRICTED	AddressLine2
City	RESTRICTED	City
State	RESTRICTED	State
ZIP Code	RESTRICTED	ZIPCode

Field	Value	IRS element (for citing)
Total Contributions	RESTRICTED	TotalContributionsAmt

Schedule C IRS990ScheduleC

Field	Value	IRS element (for citing)
Total Grassroots Lobbying		TotalGrassrootsLobbyingGrp
Total Direct Lobbying		TotalDirectLobbyingGrp
Total Lobbying Expend		TotalLobbyingExpendGrp
Other Exempt Purpose Expend		OtherExemptPurposeExpendGrp
Total Exempt Purpose Expend		TotalExemptPurposeExpendGrp
Lobbying Nontaxable Amount		LobbyingNontaxableAmountGrp
Grassroots Nontaxable		GrassrootsNontaxableGrp
Tot Lbbyng Grassroot Mns Non Tx		TotLbbyngGrassrootMnsNonTxGrp
Tot Lbby Expend Mns Lbbyng Non Tx		TotLbbyExpendMnsLbbyngNonTxGrp
Volunteers	false	VolunteersInd
Paid Staff Or Management	Yes (true)	PaidStaffOrManagementInd
Media Advertisements	false	MediaAdvertisementsInd
Mailings Members	false	MailingsMembersInd
Publications Or Broadcast	false	PublicationsOrBroadcastInd
Grants Other Organizations	false	GrantsOtherOrganizationsInd
Direct Contact Legislators	Yes (true)	DirectContactLegislatorsInd
Direct Contact Legislators	$2,125	DirectContactLegislatorsAmt
Rallies Demonstrations	false	RalliesDemonstrationsInd
Other Activities	Yes (true)	OtherActivitiesInd
Other Activities	$48,314	OtherActivitiesAmt
Total Lobbying Expenditures	$50,439	TotalLobbyingExpendituresAmt
Not Described Section501c3	false	NotDescribedSection501c3Ind

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	LOBBYING ACTIVITIES	FormAndLineReferenceDesc
Explanation	SCHEDULE C, PART II-B, LINES 1G & 1I THROUGH ITS LEGISLATIVE CONSULTANTS, NYGC ADVOCATES AT THE STATE AND LOCAL LEVEL FOR GOVERNMENT FUNDS TO SUPPORT CURRENT OPERATIONS AND/OR EXPAND RESEARCH OPPORTUNITIES AT NYGC. NYGC ALSO MAINTAINS MEMBERSHIPS IN SEVERAL IRC SECTION 501(C)(6) ORGANIZATIONS THAT REPRESENT THE INTERESTS OF THE MEDICAL RESEARCH COMMUNITY; $3,064 OF THE DUES THAT NYGC PAID TO THESE ASSOCIATIONS WERE ATTRIBUTABLE TO LOBBYING IN 2019. ADDITIONALLY, NYGC STAFF MAY, FROM TIME TO TIME, CONTACT FEDERAL LEGISLATORS OR THEIR STAFF TO ENCOURAGE THEIR SUPPORT FOR MATTERS OF CONCERN TO THE ACADEMIC MEDICAL RESEARCH COMMUNITY. SUCH CONTACT MAY INCLUDE WRITING LETTERS OR OCCASIONAL MEETINGS WITH PUBLIC OFFICIALS. THE APPROXIMATE COST ASSOCIATED WITH NYGC'S COMMUNICATIONS WITH THE FEDERAL GOVERNMENT IN 2019 IS $2,125.	ExplanationTxt

Schedule D IRS990ScheduleD

Field	Value	IRS element (for citing)
Art Public Exhibition Amounts		ArtPublicExhibitionAmountsGrp
Held Works Art		HeldWorksArtGrp
CY Minus3 Yr Endwmt Fund		CYMinus3YrEndwmtFundGrp
CY Minus4 Yr Endwmt Fund		CYMinus4YrEndwmtFundGrp
Land		LandGrp
Buildings		BuildingsGrp

Leasehold Improvements LeaseholdImprovementsGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$70,852,332	OtherCostOrOtherBasisAmt
Depreciation	$18,936,299	DepreciationAmt
Book Value	$51,916,033	BookValueAmt

Equipment EquipmentGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$30,652,288	OtherCostOrOtherBasisAmt
Depreciation	$28,251,470	DepreciationAmt
Book Value	$2,400,818	BookValueAmt

Other Land Buildings OtherLandBuildingsGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$28,404,370	OtherCostOrOtherBasisAmt
Depreciation	$25,049,820	DepreciationAmt
Book Value	$3,354,550	BookValueAmt

Field	Value	IRS element (for citing)
Total Book Value Land Buildings	$57,671,401	TotalBookValueLandBuildingsAmt

Other Assets Org OtherAssetsOrgGrp (2 entries)

DescDesc	Book ValueBookValueAmt
SECURITY DEPOSITS	$9,172,240
DEFERRED COMPENSATION	$370,154

Field	Value	IRS element (for citing)
Total Book Value Other Assets	$9,542,394	TotalBookValueOtherAssetsAmt
Federal Income Tax Liability	$0	FederalIncomeTaxLiabilityAmt

Other Liabilities Org OtherLiabilitiesOrgGrp (2 entries)

DescDesc	AmtAmt
ACCRUED INTEREST PAYABLE	$6,493
DEFERRED RENT	$25,961,363

Field	Value	IRS element (for citing)
Total Liability	$25,967,856	TotalLiabilityAmt
Footnote Text	Yes (X)	FootnoteTextInd
Total Rev Etc Audited Fincl Stmt	$45,525,304	TotalRevEtcAuditedFinclStmtAmt
Revenue Subtotal	$45,525,304	RevenueSubtotalAmt
Other Revenues Not Included	-$3,280,859	OtherRevenuesNotIncludedAmt
Revenue Not Reported Fincl Stmt	-$3,280,859	RevenueNotReportedFinclStmtAmt
Total Revenue Per Form990	$42,244,445	TotalRevenuePerForm990Amt
Tot Expns Etc Audited Fincl Stmt	$83,480,627	TotExpnsEtcAuditedFinclStmtAmt
Other Expenses Included	$3,280,859	OtherExpensesIncludedAmt
Expenses Not Reported	$3,280,859	ExpensesNotReportedAmt
Expenses Subtotal	$80,199,768	ExpensesSubtotalAmt
Total Expenses Per Form990	$80,199,768	TotalExpensesPerForm990Amt

Supplemental Information Detail SupplementalInformationDetail (2 entries)

Form And Line ReferenceFormAndLineReferenceDesc

ExplanationExplanationTxt

INCOME TAXES

SCHEDULE D, PART X, LINE 2 NYGC IS SUBJECT TO THE PROVISIONS OF THE FASB ASC SECTION 740-10-05, INCOME TAXES - OVERALL, RELATING TO ACCOUNTING AND REPORTING FOR UNCERTAINTY IN INCOME TAXES. NYGC RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE POSITIONS ARE MORE LIKELY THAN NOT OF BEING SUSTAINED AND HAS DETERMINED IT DID NOT HAVE ANY EXPOSURE TO UNCERTAIN TAX POSITIONS DURING 2019 AND 2018.

REVENUE AND EXPENSE RECONCILIATION

SCHEDULE D, PART XI, LINE 4B AND PART XII, LINE 2D ($3,280,859) - RENTAL EXPENSES ALLOCABLE TO 990, PART VIII

Schedule F IRS990ScheduleF

Field	Value	IRS element (for citing)
Grant Records Maintained	Yes (true)	GrantRecordsMaintainedInd

Account Activities Outside US AccountActivitiesOutsideUSGrp (3 entries)

RegionRegionTxt	OfficesOfficesCnt	EmployeeEmployeeCnt	Type Of Activities ConductedTypeOfActivitiesConductedTxt	Specific Services ProvidedSpecificServicesProvidedTxt	Region Total ExpendituresRegionTotalExpendituresAmt
Europe (Including Iceland and Greenland)	0	8	Program Services	RESEARCH	$155,453
North America	0	3	Program Services	RESEARCH	$5,863
Europe (Including Iceland and Greenland)			Program Services	COLLABORATION	$137,301

Field	Value	IRS element (for citing)
Subtotal Offices	0	SubtotalOfficesCnt
Subtotal Employees	11	SubtotalEmployeesCnt
Total Office	0	TotalOfficeCnt
Total Employee	11	TotalEmployeeCnt
Subtotal Spent	$298,617	SubtotalSpentAmt
Total Spent	$298,617	TotalSpentAmt

Grants To Org Outside US GrantsToOrgOutsideUSGrp (2 entries)

RegionRegionTxt	Purpose Of GrantPurposeOfGrantTxt	Cash GrantCashGrantAmt	Manner Of Cash DisbursementMannerOfCashDisbursementTxt
Europe (Including Iceland and Greenland)	research subaward	$37,301	WIRE
Europe (Including Iceland and Greenland)	RESEARCH	$100,000	WIRE

Field	Value	IRS element (for citing)
Total501c3 Org	2	Total501c3OrgCnt
Transfer To Foreign Corp	false	TransferToForeignCorpInd
Interest In Foreign Trust	false	InterestInForeignTrustInd
Foreign Corp Ownership	false	ForeignCorpOwnershipInd
Passive Foreign Investmest Co	false	PassiveForeignInvestmestCoInd
Foreign Partnership	false	ForeignPartnershipInd
Boycott Countries	false	BoycottCountriesInd

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	accounting method	FormAndLineReferenceDesc
Explanation	SCHEDULE F, PART I, LINE 3 THE PROGRAM EXPENDITURES ARE REPORTED ON THE ACCRUAL METHOD. MONITORING USE OF GRANT FUNDS SCHEDULE F, PART I, LINE 2 NYGC MONITORS SUBRECIPIENTS' USE OF GRANT FUNDS IN BOTH THE PREAWARD AND POST-AWARD STAGES IN COMPLIANCE WITH 2 CFR.200 (UNIFORM GUIDANCE). THIS REVIEW INCLUDES CONDUCTING APPROPRIATE CHECKS FOR SUSPENSION AND DEBARMENT. A SUBRECIPIENT MONITORING FORM IS SENT TO ALL SUB-AWARDEES AND THIS FORM IS THE BASIS BY WHICH NYGC ASSESSES RISK. IN THE POST-AWARD PHASE, NYGC MONITORS PROGRAMMATIC PROGRESS IN A MANNER CONSISTENT WITH THE TERMS AND CONDITIONS OF THE AWARD. NYGC REVIEWS ANY SUBRECIPIENT EXPENSES INVOICED TO NYGC FOR ALLOWABILITY WITH REGARD TO RELEVANT COST PRINCIPLES AND BUDGETARY RESTRICTIONS BEFORE PAYMENT. SUBAWARDS ELIGIBLE FOR FFATA REPORTING ARE RECORDED IN THE FSRS (THE FFATA SUBAWARD REPORTING SYSTEM) IN ACCORDANCE WITH THE FEDERAL REPORTING REQUIREMENTS FOR FIRST TIER SUBAWARDS UNDER NYGC'S PRIME FEDERAL AWARDS.	ExplanationTxt

Schedule G IRS990ScheduleG

Field	Value	IRS element (for citing)
In Person Solicitations	Yes (X)	InPersonSolicitationsInd
Agrmt Prof Fundraising Acty	Yes (true)	AgrmtProfFundraisingActyInd

Fundraiser Activity Info FundraiserActivityInfoGrp

Field	Value	IRS element (for citing)
Person	COMMUNITY COUNSELLING SERVICE	PersonNm
Activity	CAMPAIGN SERVICES	ActivityTxt
Fundraiser Control Of Funds	false	FundraiserControlOfFundsInd
Retained By Contractor	$120,056	RetainedByContractorAmt
Net To Organization	-$120,056	NetToOrganizationAmt

Field	Value	IRS element (for citing)
Total Retained By Contractors	$120,056	TotalRetainedByContractorsAmt
Total Net To Organization	-$120,056	TotalNetToOrganizationAmt
Licensed States	AL	LicensedStatesCd
Licensed States	AK	LicensedStatesCd
Licensed States	AR	LicensedStatesCd
Licensed States	CA	LicensedStatesCd
Licensed States	CO	LicensedStatesCd
Licensed States	CT	LicensedStatesCd
Licensed States	FL	LicensedStatesCd
Licensed States	GA	LicensedStatesCd
Licensed States	HI	LicensedStatesCd
Licensed States	IL	LicensedStatesCd
Licensed States	KS	LicensedStatesCd
Licensed States	KY	LicensedStatesCd
Licensed States	LA	LicensedStatesCd
Licensed States	ME	LicensedStatesCd
Licensed States	MD	LicensedStatesCd
Licensed States	MA	LicensedStatesCd
Licensed States	MI	LicensedStatesCd
Licensed States	MS	LicensedStatesCd
Licensed States	MO	LicensedStatesCd
Licensed States	MT	LicensedStatesCd
Licensed States	NH	LicensedStatesCd
Licensed States	NJ	LicensedStatesCd
Licensed States	NM	LicensedStatesCd
Licensed States	NY	LicensedStatesCd
Licensed States	NC	LicensedStatesCd
Licensed States	ND	LicensedStatesCd
Licensed States	OH	LicensedStatesCd
Licensed States	OK	LicensedStatesCd
Licensed States	OR	LicensedStatesCd
Licensed States	PA	LicensedStatesCd
Licensed States	RI	LicensedStatesCd
Licensed States	SC	LicensedStatesCd
Licensed States	TN	LicensedStatesCd
Licensed States	UT	LicensedStatesCd
Licensed States	VA	LicensedStatesCd
Licensed States	WA	LicensedStatesCd
Licensed States	WV	LicensedStatesCd
Licensed States	WI	LicensedStatesCd

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	Schedule G, Part I, Line 2b	FormAndLineReferenceDesc
Explanation	COMMUNITY COUNSELLING SERVICE'S ADDRESS: 527 MADISON AVENUE 5TH FLOOR NEW YORK, NY 10022 SCHEDULE G, PART I, LINE 2B, COLUMN (IV) NYGC UTILIZES THE SERVICES OF A FUNDRAISING ADVISOR TO CONSULT ON THE DEVELOPMENT ACTIVITIES OF THE ORGANIZATION. THE ADVISOR OFFERS ADVICE ON STRATEGY AND IS NOT INVOLVED IN DIRECT FUNDRAISING. DUE TO THE NATURE OF THESE ARRANGEMENTS, NYGC IS UNABLE TO REASONABLY DETERMINE THE GROSS RECEIPTS FROM THE FUNDRAISING ACTIVITIES THAT ARE SOLELY ATTRIBUTABLE TO THIS ADVISOR.	ExplanationTxt

Schedule I IRS990ScheduleI

Field	Value	IRS element (for citing)
Grant Records Maintained	Yes (true)	GrantRecordsMaintainedInd

Recipient Table RecipientTable (11 entries)

Address Line1USAddress/AddressLine1Txt	CityUSAddress/CityNm	State AbbreviationUSAddress/StateAbbreviationCd	ZIPUSAddress/ZIPCd	Recipient EINRecipientEIN	IRC SectionIRCSectionDesc	Cash GrantCashGrantAmt	Purpose Of GrantPurposeOfGrantTxt	Address Line2USAddress/AddressLine2Txt
TRUSTEES OF COLUMBIA UNIVERSITY CITY OF NY
630 W 168TH ST	NEW YORK	NY	10032	135598093	501(C)(3)	$323,877	RESEARCH SUBAWARD
COLD SPRING HARBOR LABORATORY
1 BUNGTOWN RD	COLD SPRING HARBOR	NY	11724	112013303	501(C)(3)	$501,045	RESEARCH SUBAWARD
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
ONE GUSTAVE L LEVY PL	NEW YORK	NY	10029	136171197	501(C)(3)	$39,571	RESEARCH SUBAWARD	BOX 1075
REGENTS OF THE UNIVERSITY OF CALIFORNIA-SF
1550 4TH STREET	SAN FRANCISCO	CA	94158	946036493	CA	$22,364	RESEARCH SUBAWARD
REGENTS OF THE UNIVERSITY OF CALIFORNIA-LA
11000 KINROSS AVE	LOS ANGELES	CA	90095	956006143	CA	$45,530	RESEARCH SUBAWARD
UNIVERSITY OF WASHINGTON
4333 BROOKLYN AVE NE	SEATTLE	WA	98195	916001537	WA	$225,498	RESEARCH SUBAWARD
THE ROCKEFELLER UNIVERSITY
1230 YORK AVENUE	NEW YORK	NY	10064	131624158	501(C)(3)	$271,894	RESEARCH SUBAWARD
Massachusetts General Hospital
55 Fruit Street	Boston	MA	021142696	042697983	501(C)(3)	$39,958	RESEARCH SUBAWARD
Johns Hopkins University
3400 N Charles St	BALTIMORE	MD	21218	520595110	501(c)(3)	$36,683	RESEARCH SUBAWARD
The Broad Institute Inc
415 Main St	CAMBRIDGE	MA	02142	263428781	501(c)(3)	$171,017	RESEARCH SUBAWARD
Weill Cornell Medical College
1300 York Ave	New York	NY	10065	150532082	501(c)(3)	$8,156	RESEARCH SUBAWARD

Field	Value	IRS element (for citing)
Total501c3 Org	11	Total501c3OrgCnt

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	MONITORING USE OF GRANT FUNDS	FormAndLineReferenceDesc
Explanation	SCHEDULE I, PART I, LINE 2 NYGC MONITORS SUBRECIPIENTS' USE OF GRANT FUNDS IN BOTH THE PREAWARD AND POST-AWARD STAGES IN COMPLIANCE WITH 2 CFR.200 (UNIFORM GUIDANCE). THIS REVIEW INCLUDES CONDUCTING APPROPRIATE CHECKS FOR SUSPENSION AND DEBARMENT. A SUBRECIPIENT MONITORING FORM IS SENT TO ALL SUB-AWARDEES AND THIS FORM IS THE BASIS BY WHICH NYGC ASSESSES RISK. IN THE POST-AWARD PHASE, NYGC MONITORS PROGRAMMATIC PROGRESS IN A MANNER CONSISTENT WITH THE TERMS AND CONDITIONS OF THE AWARD. NYGC REVIEWS ANY SUBRECIPIENT EXPENSES INVOICED TO NYGC FOR ALLOWABILITY WITH REGARD TO RELEVANT COST PRINCIPLES AND BUDGETARY RESTRICTIONS BEFORE PAYMENT. SUBAWARDS ELIGIBLE FOR FFATA REPORTING ARE RECORDED IN THE FSRS (THE FFATA SUBAWARD REPORTING SYSTEM) IN ACCORDANCE WITH THE FEDERAL REPORTING REQUIREMENTS FOR FIRST TIER SUBAWARDS UNDER NYGC'S PRIME FEDERAL AWARDS.	ExplanationTxt

Schedule J IRS990ScheduleJ

Field	Value	IRS element (for citing)
Idemnification Gross Up Pmts	Yes (X)	IdemnificationGrossUpPmtsInd
Housing Allowance Or Residence	Yes (X)	HousingAllowanceOrResidenceInd
Written Policy Ref T And E Expnss	Yes (true)	WrittenPolicyRefTAndEExpnssInd
Substantiation Required	Yes (true)	SubstantiationRequiredInd
Board Or Committee Approval	Yes (X)	BoardOrCommitteeApprovalInd
Severance Payment	Yes (true)	SeverancePaymentInd
Supplemental Nonqual Rtr Plan	Yes (true)	SupplementalNonqualRtrPlanInd
Equity Based Comp Arrngm	false	EquityBasedCompArrngmInd
Comp Based On Revenue Of Flng Org	false	CompBasedOnRevenueOfFlngOrgInd
Comp Bsd On Rev Related Orgs	false	CompBsdOnRevRelatedOrgsInd
Comp Bsd Net Earns Flng Org	false	CompBsdNetEarnsFlngOrgInd
Comp Bsd Net Earns Rltd Orgs	false	CompBsdNetEarnsRltdOrgsInd
Any Non Fixed Payments	Yes (true)	AnyNonFixedPaymentsInd
Initial Contract Exception	false	InitialContractExceptionInd

Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (15 entries)

TitleTitleTxt	Base Compensation Filing OrgBaseCompensationFilingOrgAmt	Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt	Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt	Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt	Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt	Total Compensation Filing OrgTotalCompensationFilingOrgAmt	Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt	Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt	Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt	Other Compensation Filing OrgOtherCompensationFilingOrgAmt	Bonus Filing OrganizationBonusFilingOrganizationAmount
Tom Maniatis PHD
SCIENTIFIC DIR & CEO	$582,430	$0	$0	$0	$0	$582,430	$0	$0	$0
CHERYL A MOORE
PRESIDENT & COO	$918,991	$214,000	$0	$4,228	$0	$2,058,410	$0	$642,337	$0	$921,191
ELIZABETH BROOKS O'BRIEN
VICE PRESIDENT & GEN. COUNSEL	$419,097	$14,000	$0	$30,284	$0	$463,381	$0	$0	$0
ANA LUCIA BASTIANI-POSNER
SVP, Finance and Admin	$386,106	$14,000	$0	$3,268	$0	$403,374	$0	$0	$0
CAROL ASHE
CHIEF BUSINESS OFFICER	$414,579	$14,000	$0	$117	$0	$428,696	$0	$0	$0
KATHLEEN MCGOVERN KEARNs
VICE PRESIDENT, DEV'T & COMM	$399,020	$10,893	$0	$16,775	$0	$426,688	$0	$0	$0
CHARLES GAGNON
SENIOR DIR, IT INFRASTRUCTURE	$273,903	$14,000	$0	$27,224	$0	$315,127	$0	$0	$0
TOBY BLOOM
Former Key Employee	$159,212	$8,934	$0	$8,887	$0	$319,341	$0	$0	$0	$142,308
SOREN GERMER
SVP, Genome Technologies	$306,981	$14,000	$0	$15,347	$0	$337,502	$0	$0	$0		$1,174
MICHAEL CHARLES ZODY
Scientific Dir, COMP BIOLOGY	$197,824	$7,866	$0	$8,109	$0	$213,799	$0	$0	$0
DAYNA M OSCHWALD
chief of staff, office sci dir	$241,858	$8,164	$0	$15,347	$0	$275,191	$0	$0	$0		$9,822
HANNAH GOULDING
Senior Director, HR	$213,006	$10,650	$0	$117	$0	$223,773	$0	$0	$0
MELISSA PROBER
Senior Associate Counsel	$212,663	$7,584	$0	$2,217	$0	$222,464	$0	$0	$0
CHRISTOPHER PHIFER BLACK
DIRECTOR, RESEARCH COMPUTING	$206,054	$10,628	$0	$25,354	$0	$242,036	$0	$0	$0
SHAILAJA GARGEYA
SENIOR DIR, SOFTWARE ENGINEER	$308,508	$14,000	$0	$2,877	$0	$333,167	$0	$0	$0		$7,782

Supplemental Information Detail SupplementalInformationDetail (3 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
SCHEDULE J, PART I, LINE 1	TAX INDEMNIFICATION AND GROSS-UP PAYMENTS NYGC PAYS TAXES ON BEHALF OF ITS PRESIDENT & CHIEF OPERATING OFFICER (COO) VIA A PAYROLL TAX GROSS UP FOR LIFE INSURANCE, DISABILITY AND LONG-TERM CARE BENEFITS PURSUANT TO HER OFFER LETTER. AN EXECUTIVE COMPENSATION COMMITTEE OF INDEPENDENT BOARD MEMBERS IS RESPONSIBLE FOR ESTABLISHING HER COMPENSATION PACKAGE, WHICH IS THEN APPROVED BY THE BOARD OF DIRECTORS. HOUSING ALLOWANCE OR RESIDENCE FOR PERSONAL USE NYGC PROVIDES A HOUSING ALLOWANCE TO THE SCIENTIFIC DIRECTOR & CHIEF EXECUTIVE OFFICER (CEO) AND PRESIDENT & COO. NYGC SELECTIVELY OFFERS HOUSING ALLOWANCES TO EMPLOYEES, PRINCIPALLY AS A RECRUITING TOOL FOR NEW FACULTY AND POSTDOCTORAL FELLOWS. SUBSIDIZED HOUSING OR HOUSING ALLOWANCES ARE COMMONLY OFFERED BY PEER ACADEMIC INSTITUTIONS IN NEW YORK CITY TO HELP FACULTY AND OTHER RESEARCHERS DEFRAY THE HIGH COST OF HOUSING. THE VALUE OF THIS ASSISTANCE IS TREATED AS TAXABLE COMPENSATION TO THE EMPLOYEE.
EXECUTIVE COMPENSATION	SCHEDULE J, PART I, LINE 3 IN 2019, NYGC'S SCIENTIFIC DIRECTOR & CEO WAS EMPLOYED BY AN UNRELATED ENTITY AND LEASED TO NYGC TO DEVOTE 80% OF HIS TIME AND EFFORT TO SERVING AS NYGC'S SCIENTIFIC DIRECTOR & CEO, AN OFFICER OF THE CORPORATION AND AS AN ASSOCIATE MEMBER OF NYGC'S FACULTY. HIS NYGC COMPENSATION IS 80% OF THE COMPENSATION THAT IS SET BY THE UNRELATED ENTITY. HE OVERSAW NYGC'S RESEARCH PROGRAM AND UNDERTOOK OTHER ACTIVITIES AS NYGC'S BOARD OF DIRECTORS REQUESTED FROM TIME TO TIME. THE SCIENTIFIC DIRECTOR & CEO DEVOTED 20% OF HIS TIME TO HIS DUTIES AT THE UNRELATED ENTITY, WHERE HE MAINTAINS A LABORATORY AND CONDUCTS INDEPENDENT, INVESTIGATOR-INITIATED RESEARCH PROJECTS. HIS COMPENSATION WAS ESTABLISHED BY THE UNRELATED ENTITY, WHO IS HIS EMPLOYER, AND IS NOT CONTROLLED BY NYGC. HOWEVER, IN LATE 2018, NYGC HIRED AN INDEPENDENT COMPENSATION CONSULTANT TO PERFORM AN EXECUTIVE TOTAL COMPENSATION STUDY OF SENIOR MANAGEMENT'S COMPENSATION, INCLUDING THE SCIENTIFIC DIRECTOR & CEO. RESULTS OF THIS STUDY WERE PROVIDED TO THE AD-HOC COMPENSATION COMMITTEE IN EARLY 2019 AND THE COMMITTEE DISCUSSED THEM. THE REVIEW SHOWED THAT THE COMPENSATION PAID TO ALL MEMBERS OF SENIOR MANAGEMENT, INCLUDING THE CEO, WAS REASONABLE. ON RECOMMENDATION OF THE AD-HOC COMMITTEE, THE BOARD OF DIRECTORS APPROVED A 5% MERIT INCREASE TO THE BASE SALARY OF THE SCIENTIFIC DIRECTOR & CEO FOR 2019. THIS APPROVAL WAS MEMORIALIZED IN THE BOARD MINUTES. WHILE THE SCIENTIFIC DIRECTOR & CEO'S COMPENSATION IS SET BY AN UNRELATED ENTITY, THE AD-HOC COMPENSATION COMMITTEE COMMUNICATED WITH THE UNRELATED ENTITY AND APPROVED HIS MERIT INCREASE IN 2019. THE SCIENTIFIC DIRECTOR & CEOS 5% MERIT INCREASE WAS BASED ON HIS FULL COMPENSATION AT THE UNRELATED ENTITY. HIS COMPENSATION AT NYGC IS 80% OF THE COMPENSATION THAT IS SET BY THE UNRELATED ENTITY. SEVERANCE PAYMENTS SCHEDULE J, PART I, LINE 4A TOBY BLOOM, FORMER KEY EMPLOYEE - MS. BLOOM'S COMPENSATION INCLUDES A SEVERANCE PAYMENT OF $125,000.
SUPPLEMENTAL NONQUALIFIED RETIREMENT PLAN	SCHEDULE J, PART I, LINE 4B and Part II NYGC HAS A DEFERRED COMPENSATION PLAN FOR THE PRESIDENT & COO. IN 2019, $200,000 WAS DEFERRED AND $642,337.32, DEFERRED FROM PRIOR YEARS, WAS DISTRIBUTED. The distribution is reported as taxable income on Part II, column (B)(iii) and column (F). NON-FIXED PAYMENTS SCHEDULE J, PART I, LINE 7 THE FOLLOWING INDIVIDUALS RECEIVED DISCRETIONARY BONUSES IN 2019: SVP, GENOME TECHNOLOGIES, CHIEF OF STAFF, OFFICE OF SCIENTIFIC DIRECTOR AND CEO AND SENIOR DIRECTOR, SOFTWARE ENGINEERING.

Schedule L IRS990ScheduleL

Bus Tr Involve Interested Prsn BusTrInvolveInterestedPrsnGrp

Name Of Interested NameOfInterested

Field	Value	IRS element (for citing)
Person	SILAS MANIATIS	PersonNm

Field	Value	IRS element (for citing)
Relationship Description	FAMILY MEMBER	RelationshipDescriptionTxt
Transaction	$135,701	TransactionAmt
Transaction	COMPENSATION	TransactionDesc
Sharing Of Revenues	false	SharingOfRevenuesInd

Schedule O IRS990ScheduleO

Supplemental Information Detail SupplementalInformationDetail (10 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
THE ORGANIZATIONS MISSION	FORM 990, PART I, LINE 1 & PART III, LINE 1: NYGC IS ORGANIZED AND OPERATED AS AN INDEPENDENT, NON-PROFIT CORPORATION, DEDICATED TO STATE-OF-THE-ART, WORLD-CLASS GENOMIC RESEARCH, SEQUENCING AND BIOINFORMATICS, WHOSE MEMBERS INCLUDE LEADING ACADEMIC, MEDICAL AND RESEARCH INSTITUTIONS. IT CREATES AND USES ADVANCED GENOMICS TO UNDERSTAND THE GENETIC BASIS OF DISEASE. NYGC HAS THE FOLLOWING KEY OBJECTIVES: (I) FOSTERING INTELLECTUALLY VIBRANT RESEARCH COLLABORATIONS IN THE ACADEMIC AND SCIENTIFIC COMMUNITY IN NEW YORK CITY, ACROSS THE COUNTRY AND AROUND THE WORLD; (II) RECRUITING AND RETAINING WORLD-CLASS SCIENTIFIC TALENT TO LEAD THE SCIENTIFIC DEVELOPMENT OF THE ORGANIZATION; (III) SUPPORTING RESEARCH CONDUCTED BY THE INSTITUTIONAL FOUNDING MEMBERS, OTHER ACADEMIC, RESEARCH AND MEDICAL INSTITUTIONS, AND THE BIOTECHNOLOGY/PHARMACEUTICAL INDUSTRY TO ADVANCE NYGCS SCIENTIFIC PROGRAM AND GENOMIC RESEARCH; (IV) DEVELOPING INNOVATIVE EXPERIMENTAL AND COMPUTATIONAL GENOMIC METHODS BASED UPON THE RESEARCH AND SEQUENCING ACTIVITIES CONDUCTED AT THE ORGANIZATION'S FACILITY, FOR THE BROADER BENEFIT OF THE RESEARCH COMMUNITY; (V) ADVANCING RESEARCH TO SUPPORT THE DEVELOPMENT OF NEW TREATMENTS, THERAPIES AND THERAPEUTICS TO TREAT HUMAN DISEASE; (VI) PROVIDING TRAINING TO THE ACADEMIC, RESEARCH AND TECHNOLOGY COMMUNITIES; AND (VII) CONDUCTING ACTIVITIES ANCILLARY TO THESE OBJECTIVES. FORM 990, PART III, LINE 4A (CONTINUED) IN 2019, NYGC SEQUENCED OVER 12,000 WHOLE GENOME SAMPLES, COMPLETED 490 PROJECTS, AND COLLABORATED WITH 131 INVESTIGATORS FROM 92 INSTITUTIONS WORLDWIDE. PROGRAM SERVICE ACCOMPLISHMENTS FORM 990, PART III, LINE 4A & LINE 4B: NYGC IS AN INDEPENDENT, NONPROFIT ACADEMIC RESEARCH INSTITUTION WITH THE MISSION OF ADVANCING CLINICAL CARE THROUGH TRANSFORMATIVE GENOMIC RESEARCH. NYGC'S WORK BUILDS ON THE EXPERTISE AND EXPERIENCE THAT NYGC HAS DEVELOPED SINCE ITS FOUNDING IN 2010 AND AUGMENTS RESEARCH BEING CONDUCTED BY NYGC MEMBER INSTITUTIONS. COLLABORATING WITH PREMIER ACADEMIC, MEDICAL AND INDUSTRY LEADERS ACROSS THE GLOBE, NYGC IS CONDUCTING DISEASE-BASED GENOMIC RESEARCH IN AREAS WHERE IT HAS DEVELOPED A STRONG AND SUCCESSFUL TRACK RECORD, PARTICULARLY IN NEURODEGENERATIVE DISEASES SUCH AS ALS, NEUROPSYCHIATRIC DISEASES, PRINCIPALLY IN AUTISM, AND CANCER, FOCUSING ON UNDERSERVED POPULATIONS AND RARE CANCERS, AMONG OTHERS. IN 2020, NYGC ALSO EXPANDED ITS EXPERTISE TO COVID-19 RESEARCH. THROUGH INNOVATIVE RESEARCH AND GENOMIC DISCOVERY, NYGC'S GOAL IS TO ADVANCE HUMAN HEALTH. NYGC, ITS MEMBER INSTITUTIONS AND PARTNERS ARE UNITED IN THIS UNPRECEDENTED COLLABORATION OF TECHNOLOGY, SCIENCE AND MEDICINE, DESIGNED TO HARNESS THE POWER OF INNOVATION AND GENOMICS TO MAKE GROUNDBREAKING NEW DISCOVERIES IN THESE DISEASES. THEIR SHARED OBJECTIVE IS THE ACCELERATION OF MEDICAL GENOMICS TO BENEFIT PATIENTS AROUND THE WORLD. NYGC'S INNOVATION, RESEARCH AND QUALITY MAKE IT A UNIQUE AND STRONG COLLABORATIVE PARTNER IN GENOMICS. NYGCS SCIENTIFIC MISSION BUILDS ON THE COLLABORATIVE RESEARCH PROJECTS AMONG NYGC FACULTY MEMBERS AND STAFF SCIENTISTS WITH SCIENTISTS AND CLINICIANS FROM MEMBER INSTITUTIONS, AN AFFILIATE MEMBERSHIP PROGRAM, DISEASE- AND TECHNOLOGY-CENTERED WORKING GROUPS AND INDUSTRY PARTNERS. IN 2019, NYGC CONTINUED TO EXPAND ITS AFFILIATE MEMBERSHIP PROGRAM, WHICH NOW TOTALS 80 MEMBERS, HAILING FROM 14 ACADEMIC INSTITUTIONS ACROSS THE COUNTRY. RESEARCH AND FACULTY --------------------- SINCE ITS INCEPTION, NYGC HAS ATTRACTED WORLD-CLASS SCIENTISTS WHOSE GENOMIC EXPERTISE - INCLUDING SINGLE CELL GENOMICS, GENOME ENGINEERING, POPULATION, FUNCTIONAL AND EVOLUTIONARY GENOMICS, TECHNOLOGY AND METHODS DEVELOPMENT, STATISTICS, COMPUTATIONAL BIOLOGY AND BIOENGINEERING - BRING A MULTIDISCIPLINARY AND IN-DEPTH APPROACH TO THE EVOLVING FIELD OF GENOMICS. NYGC'S FACULTY SUPPORT NYGC'S SCIENTIFIC VISION THROUGH THE ADVANCEMENT OF TECHNOLOGY DEVELOPMENT AND GENOMIC MEDICINE. FACULTY MEMBERS HAVE JOINT APPOINTMENTS AT THE NYGC'S INSTITUTIONAL FOUNDING MEMBERS TO PROMOTE COLLABORATION, STRENGTHEN RESEARCH CAPABILITIES, ADVANCE ACADEMIC LEADERSHIP, AND ENHANCE OUR ABILITY TO UNDERSTAND AND HELP TREAT HUMAN DISEASES. IN 2019, NYGC MANAGED 56 GRANTS FROM THE NATIONAL INSTITUTES OF HEALTH (NIH). NYGC'S RESEARCHERS ARE WORKING WITH ITS MEMBER INSTITUTIONS AND COLLABORATIVE PARTNERS TO ADDRESS THE FUNDAMENTAL CHALLENGE IN PRECISION MEDICINE: UNDERSTANDING THE RELATIONSHIP BETWEEN DNA SEQUENCE VARIATION AND MECHANISMS OF HUMAN DISEASE, RANGING FROM CANCER TO AUTISM TO NEURODEGENERATIVE DISEASE. NYGC RESEARCHERS PUBLISHED MORE THAN 50 STUDIES IN LEADING SCIENTIFIC JOURNALS IN 2019, FUELING MOMENTUM FOR IMPORTANT COLLABORATIVE WORK. THEY COMPLETED 490 PROJECTS, AND COLLABORATED WITH 131 INVESTIGATORS FROM 92 INSTITUTIONS WORLDWIDE. NYGC FACULTY MEMBERS FOCUS THEIR RESEARCH ON THE DEVELOPMENT AND APPLICATION OF ADVANCED GENOMICS TO UNDERSTAND DISEASE.
PROGRAM SERVICE ACCOMPLISHMENTS	ACCOMPLISHMENTS IN 2019 INCLUDE: NEURODEGENERATIVE DISEASE ------------------------- GROUNDBREAKING ALS GENE EXPRESSION ATLAS REVEALED NEW INSIGHTS INTO DISEASE PROGRESSION: RESEARCHERS AT THE NYGC LED THE GLOBAL COLLABORATION THAT DEVELOPED A MULTIDIMENSIONAL GENE EXPRESSION ATLAS THAT OFFERS A PREVIOUSLY UNAVAILABLE VIEW OF DISEASE PROGRESSION IN ALS. UTILIZING SPATIAL TRANSCRIPTOMICS TECHNOLOGY, COMBINED WITH A NOVEL COMPUTATIONAL APPROACH, THE TEAM IDENTIFIED EARLY CHANGES NOT OBSERVABLE USING TRADITIONAL SEQUENCING METHODS. THEIR FINDINGS, PUBLISHED IN SCIENCE IN APRIL 2019, REVEALED NEW INSIGHTS INTO DISEASE SIGNALING PATHWAYS, SUGGESTED NEW TARGET OPPORTUNITIES FOR DESIGNING THERAPEUTICS AND TREATMENTS, AND WILL PROVIDE A FRAMEWORK FOR FURTHER MAPPING AND BETTER UNDERSTANDING OF THE DISEASE MECHANISMS OF OTHER NEURODEGENERATIVE DISEASES WITH COMMON PATHWAYS. HEMALI PHATNANI, PHD, DIRECTOR OF NYGC'S CENTER FOR GENOMICS OF NEURODEGENERATIVE DISEASE (CGND), IS SENIOR AUTHOR OF THE STUDY AND SILAS MANIATIS, PHD, STAFF SCIENTIST, IS CO-FIRST AUTHOR. THEIR COLLABORATORS INCLUDED SCIENTISTS FROM THE SIMONS FOUNDATION'S FLATIRON INSTITUTE IN NEW YORK, THE SCILIFELAB AND KTH ROYAL INSTITUTE OF TECHNOLOGY IN SWEDEN, AND NEW YORK UNIVERSITY. NYGC'S CGND'S DEVELOPMENT OF THE ALS CONSORTIUM, A GLOBAL COLLABORATION OF CLINICIANS, SCIENTISTS, GENETICISTS, AND COMPUTATIONAL BIOLOGISTS, HAS RAPIDLY GROWN OVER THE LAST FIVE YEARS TO INCLUDE MORE THAN 30 MEMBER INSTITUTIONS IN COUNTRIES AROUND THE WORLD. THE RESULT IS ALS DATA SHARING ON AN UNPARALLELED AND UNPRECEDENTED SCALE, EMPOWERING AN INTEGRATED WORLDWIDE APPROACH TO WORKING TOWARD NEW TREATMENTS AND EFFECTIVE THERAPIES FOR ALS. IN 2019, THE CGND'S COLLABORATIVE APPROACH CONTRIBUTED TO THESE SIGNIFICANT ADVANCES IN ALS RESEARCH: * A BREAKTHROUGH STUDY LED BY COLD SPRING HARBOR LABORATORY ASSOCIATE PROFESSOR MOLLY GALE HAMMELL, PHD, PUBLISHED IN CELL, REPORTED IN OCTOBER 2019, THAT IDENTIFIED THAT TDP-43 PROTEINS ARE DYSFUNCTIONAL IN ALS, CAUSING DE-SILENCING OF RETROTRANSPOSONS, KNOWNS AS "JUMPING GENES." THE STUDY USED THE NYGC ALS CONSORTIUM COHORT OF ALS PATIENT SAMPLES AS PART OF ITS DATA ANALYSIS. THE SCIENTISTS NOW SEEK TO CONFIRM WHETHER HIGH LEVELS OF THESE GENES MIGHT MIMIC A VIRAL PATHOGEN OR OTHER INFECTION IN THE TISSUES. IF SO, THESE GENES MAY BE DIRECTLY TARGETED WITH ANTIVIRAL AGENTS OR OTHER THERAPIES. DR. PHATNANI AND MEMBERS OF HER LAB ARE AMONG THE STUDY CO-AUTHORS. DR. HAMMELL IS A MEMBER OF THE NYGC'S NEURODEGENERATIVE DISEASE SCIENTIFIC WORKING GROUP. * OTHER RECENT GENETIC ASSOCIATIONS OR MAJOR VALIDATIONS OF ALS GENES USING NYGC ALS CONSORTIUM DATA INCLUDED THE IDENTIFICATION OF PKP4 AND LGALSL IN APRIL 2019 (PUBLISHED IN GENOME RESEARCH) AND KIF5A IN MARCH 2018 (PUBLISHED IN NEURON). * DR. PHATNANI IS ALSO A CO-AUTHOR OF THE MASSACHUSETTS GENERAL HOSPITAL/HARVARD MEDICAL SCHOOL-LED STUDY, PUBLISHED IN NATURE NEUROSCIENCE IN NOVEMBER 2019, THAT IDENTIFIED DNAJC7 AS A NOVEL GENE IMPLICATED IN ALS. NEUROPSYCHIATRIC DISEASE ------------------------ THROUGH A $40 MILLION GRANT AWARD FROM THE NATIONAL HUMAN GENOME RESEARCH INSTITUTE, A DIVISION OF NIH, IN 2015 THE NYGC CREATED A CENTER FOR COMMON DISEASE GENOMICS, WHICH IS ENGAGED IN LARGE-SCALE WHOLE GENOME SEQUENCING STUDIES OF AUTISM AND OTHER COMPLEX DISEASES. NYGC RESEARCHERS ARE INVOLVED IN SFARI (SIMONS FOUNDATION AUTISM RESEARCH INITIATIVE) AND SPARK (SIMONS FOUNDATION POWERING AUTISM RESEARCH FOR KNOWLEDGE) AND LEAD OR CONTRIBUTE TO AN ARRAY OF OTHER COLLABORATIVE NEUROPSYCHIATRIC DISEASE-RELATED GENOMIC STUDIES. KEY MILESTONES IN 2019 INCLUDE: 30,000 WHOLE GENOMES OF AUTISM PATIENTS AND THEIR FAMILIES SEQUENCED: THE SCALE OF THIS DATA SET, WHICH IS BEING SEQUENCED AND ANALYZED THROUGH NYGC'S CENTER FOR COMMON DISEASE GENOMICS, REACHED THIS MILESTONE BY YEAR-END 2019. IT IS ONE OF THE LARGEST DATASETS AVAILABLE FOR RESEARCHERS TO STUDY AND IS HELPING TO UNCOVER NEW INSIGHTS INTO AUTISM. NEW AUTISM RISK GENE VARIANTS IDENTIFIED: IN AUGUST 2019, SPARK RELEASED ITS PILOT STUDY, AN ANALYSIS OF EXOME SEQUENCING OF 457 AUTISM FAMILIES. THE RESEARCH TEAM INCLUDED EVAN EICHLER, PHD, UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE, AND ASSOCIATE MEMBER, NYGC, AND WAS LED BY WENDY CHUNG, MD, PHD, COLUMBIA UNIVERSITY, AND AFFILIATE MEMBER, NYGC. THROUGH THEIR ANALYSIS, THE RESEARCHERS IDENTIFIED 647 RARE VARIANTS THAT WERE PRESENT FOR THE FIRST TIME IN A FAMILY MEMBER, EITHER AS A RESULT OF A MUTATION IN THE EGG OR SPERM OF ONE OF THE PARENTS, OR A VARIANT THAT ARISES IN THE FERTILIZED EGG. THEY ALSO FOUND INDELS, WHICH ARE INSERTIONS OR DELETIONS OF BASES IN THE GENOME, THAT APPEARED AT HIGHER FREQUENCY IN THOSE WITH AUTISM AS COMPARED TO THOSE WITHOUT AUTISM. MANY OF THESE VARIANTS WERE PREVIOUSLY KNOWN TO BE ASSOCIATED WITH AUTISM, WHILE OTHERS EMERGED FOR THE FIRST TIME. THEIR STUDY WAS PUBLISHED IN NPJ GENOMIC MEDICINE. THE NEXT PHASE OF THE SPARK PROJECT WILL LEVERAGE THE WHOLE GENOME SEQUENCING AND ANALYSIS OF SOME 1,600 AUTISM FAMILIES, CONDUCTED BY NYGC RESEARCHERS. REPORTS ON THESE FINDINGS ARE EXPECTED TO BE RELEASED THROUGHOUT 2020. NIH GRANT TO STUDY SCHIZOPHRENIA/BIPOLAR/AUTISM DISEASE RISK: NYGC CORE FACULTY MEMBER TUULI LAPPALAINEN, PHD, WHO HOLDS A JOINT APPOINTMENT AT COLUMBIA UNIVERSITY, RECEIVED RENEWED NIH R01 FUNDING SUPPORT IN AUGUST 2019 FOR A PROJECT TITLED "INTEGRATIVE ANALYSIS OF GENETIC VARIATION AND TRANSCRIPTION FACTOR NETWORKS TO ELUCIDATE MECHANISMS OF MENTAL HEALTH DISORDERS." HER PROJECT, A COLLABORATION WITH COLUMBIA UNIVERSITY COLLEAGUE HARMEN BUSSEMAKER, PHD, WILL DEPLOY NUMEROUS LARGE-SCALE FUNCTIONAL GENOMIC DATA SETS AS WELL AS EXPERIMENTAL APPROACHES TO EXPLORE SCHIZOPHRENIA, BIPOLAR DISEASE AND AUTISM RISK. EXPANDED NEUROPSYCHIATRIC GENOMICS LEADERSHIP: IN FALL 2019, NYGC ANNOUNCED THE APPOINTMENT OF THOMAS LEHNER, PHD, MPH, AS SCIENTIFIC DIRECTOR OF NEUROPSYCHIATRIC DISEASE GENOMICS. DR. LEHNER JOINED NYGC AFTER A DISTINGUISHED 15-YEAR TENURE AT THE NATIONAL INSTITUTE OF MENTAL HEALTH (NIMH), A DIVISION OF NIH, WHERE HE WAS INSTRUMENTAL IN THE CONCEPTION AND DEVELOPMENT OF THE NIMH'S COMPREHENSIVE NEUROPSYCHIATRIC GENOMICS PROGRAM. DR. LEHNER IS DEVELOPING AND SPEARHEADING THE OVERARCHING SCIENTIFIC STRATEGY FOR NYGC'S NEUROPSYCHIATRIC DISEASE GENOMICS RESEARCH. INTERNATIONALLY RENOWNED GENETICIST MARY-CLAIRE KING, PHD, JOINED NYGC'S FACULTY ON A CONSULTING BASIS AS SENIOR ASSOCIATE CORE MEMBER IN NOVEMBER 2019. DR. KING IS THE AMERICAN CANCER SOCIETY PROFESSOR IN THE DEPARTMENTS OF GENOME SCIENCES AND MEDICINE AT THE UNIVERSITY OF WASHINGTON. SHE WAS THE FIRST TO SHOW THAT BREAST AND OVARIAN CANCER IS INHERITED IN SOME FAMILIES AS THE RESULT OF MUTATIONS IN THE GENE THAT SHE NAMED BRCA1, A DISCOVERY THAT HAS TRANSFORMED THE DIAGNOSIS, DRUG DEVELOPMENT AND TREATMENT OF THIS INHERITED FORM OF BREAST CANCER. MORE RECENTLY, DR. KING HAS FOCUSED ON THE GENETICS OF SCHIZOPHRENIA, CONTRIBUTING TO THE UNDERSTANDING OF COMPLEX DISEASE INHERITANCE. SHE WILL SUPPORT NYGC'S EFFORTS TO UNDERSTAND THE GENETIC BASIS OF PSYCHIATRIC DISORDERS.
CANCER	------ GENOMICS-CENTERED INITIATIVES TO ADDRESS CANCER CARE CHALLENGES ARE A KEY FOCUS OF THE GENOME CENTER CANCER GROUP (GCCG), LED BY NOBEL LAUREATE HAROLD VARMUS, MD, SENIOR ASSOCIATE CORE MEMBER, NYGC, AND LEWIS THOMAS UNIVERSITY PROFESSOR OF MEDICINE, WEILL CORNELL MEDICINE, AND CHARLES SAWYERS, MD, CHAIR, HUMAN ONCOLOGY AND PATHOGENESIS PROGRAM, MARIE-JOSE AND HENRY R. KRAVIS CHAIR, MEMORIAL SLOAN KETTERING CANCER CENTER, AND AFFILIATE MEMBER, NYGC. WITHIN THE LAST TWO YEARS, THE GCCG, COMPOSED OF CLINICIANS AND CANCER RESEARCHERS FROM NYGCS MEMBER INSTITUTIONS, INCLUDING SEVEN NCI-DESIGNATED CANCER CENTERS, HAS DEVELOPED TWO MAJOR MULTI-INSTITUTIONAL COLLABORATIONS. IN 2018, THE GROUP BEGAN WORK ON ITS POLYETHNIC-1000 PROJECT TO STUDY CANCER GENOMES OF UNDERSERVED, ETHNICALLY DIVERSE POPULATIONS. IN 2019, THE GCCG LAUNCHED THE VERY RARE CANCER CONSORTIUM, A NEW COLLABORATION TO HELP ADVANCE CLINICAL CARE FOR PATIENTS AFFECTED BY VERY RARE TUMOR TYPES. THESE PROJECTS ACHIEVED THE FOLLOWING PROGRESS MILESTONES IN 2019: POLYETHNIC-1000 ADVANCED TO EXTENSIVE PROSPECTIVE STUDY. AT AN OCTOBER 2019 RETREAT, RESEARCHERS SHARED THE FINDINGS OF THE POLYTETHNIC-1000 PROJECTS RETROSPECTIVE ANALYSIS OF OVER 100 SEQUENCED TUMOR SAMPLES FROM PATIENTS, COVERING CANCER TYPE, FREQUENCY OF GENETIC VARIATION, AND AN ESTIMATION OF GENETIC ANCESTRY. THE TEAM HAS FORGED STRONG CONNECTIONS BETWEEN ACADEMIC CENTERS AND PARTNER HOSPITALS AND IS NOW ADVANCING TO THE STUDYS NEXT PHASE, AN EXTENSIVE PROSPECTIVE STUDY OF PATIENTS. STUDY FINDINGS WILL BE STORED IN A DATABASE THAT WILL SERVE AS A GLOBAL RESOURCE FOR DEVELOPING HYPOTHESES AND UNDERSTANDING OF ETHNIC AND RACIAL DIVERSITY IN CANCER. WHERE SEQUENCING REVEALS AN ACTIONABLE MUTATION IN THE TUMOR, THE STUDY TEAM WILL VALIDATE THE RESULTS CLINICALLY AND SHARE THE INFORMATION WITH THE TREATING PHYSICIAN. THE VERY RARE CANCER CONSORTIUM LAUNCHED ITS MULTI-INSTITUTIONAL MOLECULAR TUMOR BOARD WHERE ONCOLOGISTS, HEMATOLOGISTS, SCIENTISTS, PATHOLOGISTS, COMPUTATIONAL BIOLOGISTS, AND OTHER MEMBERS OF THE CANCER GENOMICS COMMUNITY ARE CONVENING AT THE NYGC ON A REGULAR BASIS TO HOLD MULTIDISCIPLINARY MOLECULAR TUMOR BOARD MEETINGS. CLINICIANS FROM PARTICIPATING HOSPITALS REPORT CASE CONFERENCES TO THE TUMOR BOARD TO DETERMINE THE MOST EFFECTIVE TREATMENT FOR PATIENTS WITH VERY RARE CANCERS. DR. VARMUS AND OLIVIER ELEMENTO, PHD, DIRECTOR, ENGLANDER INSTITUTE FOR PRECISION MEDICINE, WEILL CORNELL MEDICINE, AND AFFILIATE MEMBER, NYGC, ARE CO-LEADING THE CONSORTIUM AND ITS TUMOR BOARD. AN NYGC SEQUENCING TEST LED TO NEW INSIGHTS INTO PANCREATIC CANCER AND IMPROVED TREATMENT FOR A PANCREATIC CANCER PATIENT IN 2019. CLINICIANS USED NYGC CLINICAL LABS WHOLE GENOME AND TRANSCRIPTOME SEQUENCING (WGTS) ONCOLOGY TEST TO INFORM THEIR TREATMENT PLAN FOR A PATIENT WITH PANCREATIC CANCER. THE WGTS ANALYSIS OF THE PATIENTS TUMOR GENOME IDENTIFIED A VARIANT THAT HAS BEEN SHOWN IN PRE-CLINICAL STUDIES TO BE SENSITIVE TO THE BRAF INHIBITOR DRUG DABRAFENIB. BASED ON THIS FINDING, CLINICIANS PROCEEDED TO TREAT THE PATIENT WITH DABRAFENIB. OVERALL, THE PATIENTS CLINICAL CONDITION IMPROVED SIGNIFICANTLY, WITH DABRAFENIB-INDUCED REMISSION LASTING FOR SIX MONTHS. THE PAPER ON THE CASE WAS PUBLISHED IN MOLECULAR CASE STUDIES IN SEPTEMBER 2019. NYGC SCIENTIST KAZ WRZESZCZYNSKI, PHD, ASSISTANT DIRECTOR, CLINICAL ONCOLOGY INFORMATICS, NYGC, IS CO-CORRESPONDING AUTHOR ON THE PAPER ON THE PANCREATIC CASE WITH SCOTT POWERS, PHD, AND MINSIG CHOI, MD, OF STONY BROOK CANCER CENTER, WITH OTHER NYGC SCIENTISTS FROM THE NYGC CLINICAL LAB AND BIOINFORMATICS AND SEQUENCING TEAMS AMONG THE CO-AUTHORS. TECHNOLOGY INNOVATION ---------------------- THE NEW GENOMICS TOOL ECCITE-SEQ DEVELOPED AT THE NYGC EXPANDED MULTIMODAL SINGLE CELL ANALYSIS. "INTERROGATION OF SINGLE CELLS TAKEN ONE STEP FURTHER," IS HOW ONE MEDIA OUTLET HERALDED THE SPRING 2019 RELEASE OF RELEASE OF ECCITE-SEQ, WHICH EXTENDS CITE-SEQ, THE POWERFUL SINGLE-CELL ANALYSIS TOOL DEVELOPED BY NYGC SCIENTISTS IN 2017, FOR USE IN COMBINATION WITH EXPLORATORY CRISPR GENE EDITING SCREENS. THE EXPANDED TECHNOLOGY WAS DEVELOPED IN A COLLABORATION LED BY THE NYGC TECHNOLOGY INNOVATION LAB WITH THE LABS OF NYGC CORE FACULTY MEMBERS NEVILLE SANJANA, PHD, AND RAHUL SATIJA, PHD, WHO HOLD JOINT APPOINTMENTS AT NYU, AND RESEARCHERS FROM THE JACKSON LABORATORY. THE TEAMS REPORT ON THE TOOL, PUBLISHED IN NATURE METHODS IN APRIL AND FEATURED ON ITS MAY 2019 COVER, INCLUDES DEMONSTRATING ECCITE-SEQS ABILITY TO FINELY DISSECT SPECIFIC CELL SUBTYPES AND CHARACTERIZE MALIGNANT POPULATIONS IN A SAMPLE FROM A PATIENT WITH CUTANEOUS T CELL LYMPHOMA. ECCITE-SEQ HAS RAPIDLY BEEN ADOPTED BY RESEARCH INSTITUTES THROUGHOUT THE WORLD, DEMONSTRATING ITS IMPORTANT IMPACT AND UTILITY TO THE FIELD. FURTHER ADVANCES ON GENOMIC TESTS AND TOOLS WERE MADE IN 2019. THE CANCER ANALYSIS TOOL GENOTYPING OF TRANSCRIPTOMES, DEVELOPED IN A COLLABORATION JOINTLY SUPERVISED BY NYGC CORE FACULTY MEMBER DAN LANDAU, MD, PHD, AND NYGC TECHNOLOGY INNOVATION LAB SENIOR MANAGER PETER SMIBERT, PHD, ENABLES MEASUREMENT OF GENE MUTATIONS AND THEIR EFFECTS ON GENE ACTIVITY WITHIN INDIVIDUAL CANCER CELLS BIOPSIED FROM PATIENTS. THE TEAMS STUDY WAS PUBLISHED IN NATURE IN JULY 2019. ANEVA (ANALYSIS OF EXPRESSION VARIATION), A NEW METHOD TO HELP DIAGNOSE RARE DISEASE, WAS DEVELOPED IN A STUDY SUPERVISED BY NYGC CORE FACULTY MEMBER TUULI LAPPALAINEN, PHD. THE METHOD FIRST TAKES DATA FROM A LARGE REFERENCE SAMPLE OF HEALTHY INDIVIDUALS. THEN, USING THE ANEVA DOSAGE OUTLIER TEST, RESEARCHERS WERE ABLE TO DIAGNOSE ADDITIONAL PATIENTS WHERE PREVIOUS METHODS OF GENOME AND RNA ANALYSIS HAD FAILED TO IDENTIFY THEIR RARE DISEASE VARIANTS. THE STUDY WAS PUBLISHED IN SCIENCE IN OCTOBER 2019. NYGCS CLINICAL LABS CLINICAL CONSTITUTIONAL WHOLE-GENOME SEQUENCING (WGS) TEST, RECEIVED NEW YORK STATE DEPARTMENT OF HEALTH APPROVAL AT YEAR-END 2019. THIS TEST OFFERS PHYSICIANS THE MOST COMPLETE PACKAGE OF GENOMIC DATA AVAILABLE FOR PATIENTS WITH UNDIAGNOSED DISEASES, AS WELL AS THOSE PATIENTS WHO ARE SEEKING PREDISPOSITIONAL GENETIC TESTING. THE NYGC BIOINFORMATICS TEAM COLLABORATED ON THE DEVELOPMENT OF AN INNOVATIVE GENOMIC TOOL IN 2017 EXPANSION HUNTER THAT IS USED IN THE WHOLE GENOME SEQUENCING TEST. IT ENABLES THE ANALYSIS OF GENETIC VARIATION IN SHORT TANDEM REPEAT REGIONS OF THE GENOME.
RESEARCH SEQUENCING	-------------------- NYGC HAS ONE OF THE LARGEST VOLUME WHOLE GENOME SEQUENCING PROGRAMS IN NEW YORK. IN THE PAST SIX YEARS, NYGC'S SEQUENCING LABORATORY HAS SEQUENCED OVER 77,000 WHOLE GENOME SAMPLES. NYGC HAS FIVE NOVASEQ SYSTEMS SEQUENCERS, WITH THE CAPACITY TO SEQUENCE OVER 40,000 GENOMES A YEAR. THIS STATE-OF-THE-ART SEQUENCING TECHNOLOGY ENABLES NYGC TO CONDUCT LARGE-SCALE GENOMICS PROJECTS WITH GREAT SPEED AND SAMPLE VOLUMES, AND TO EXPLORE THE GENOME IN MORE DEPTH WITH GREATER EFFICIENCY. NYGC'S RESEARCH SEQUENCING LAB, LED BY SOREN GERMER, PHD, SENIOR VICE PRESIDENT OF GENOME TECHNOLOGIES, PROCESSED MORE THAN 16,000 SAMPLES IN 2019, INCLUDING 12,262 WHOLE GENOME SEQUENCING SAMPLES (GERMLINE AND CANCER), 2,350 EXOME SEQUENCING SAMPLES, AND 2,200 TRANSCRIPTOME (RNA) SEQUENCING SAMPLES. OUR SUCCESS RATE FOR PASSING FLOW CELLS LANES ON THE NOVASEQ WAS 99.8%, NOT INCLUDING INSTRUMENT OR REAGENT ISSUES. AMONG OTHER LARGE COLLABORATIVE PROJECTS, SINCE 2016 NYGC HAS BEEN AWARDED $40 MILLION FROM THE NHGRI AS ONE OF THE CENTERS FOR COMMON DISEASE GENOMICS (CCDG) FOR WHOLE GENOME SEQUENCING. THROUGH THIS AWARD, THE NYGC HAS TAKEN ADVANTAGE OF ITS CLINICALLY FOCUSED, COLLABORATIVE STRUCTURE WITH AN EYE TOWARD ACHIEVING A COMPREHENSIVE UNDERSTANDING OF DIFFERENT TYPES OF COMMON DISEASES, WITH A CENTER-SPECIFIC FOCUS ON AUTISM. NYGC DECREASED THE PRICE PER GENOME BY OVER 25% SINCE THE BEGINNING OF THE PROJECT THROUGH TECHNOLOGY INNOVATION AND AUTOMATION OF ALIGNMENT AND VARIANT CALLING PIPELINES. AS A MEMBER OF THIS MULTI-INSTITUTIONAL CONSORTIUM, THE NYGC LEADS AND ENABLES COLLABORATION, COMMUNICATION, AND ANALYSIS BETWEEN CENTERS AND PRINCIPAL INVESTIGATORS, PARTICIPATING IN NUMEROUS WORKING GROUPS, STEERING COMMITTEES, AND CONFERENCES AS WELL AS LEADING THE NEUROPSYCHIATRIC WORKING GROUP, WHICH SPANS THREE INSTITUTIONS AND SEVERAL DISORDERS. IN 2019, NYGC APPLIED FOR AND RECEIVED A 5TH YEAR OF FUNDING FOR THIS PROJECT, TO FURTHER THE WHOLE GENOME SEQUENCING RESEARCH ADVANCING OUR UNDERSTANDING OF AUTISM. BY THE COMPLETION OF THE PROJECT IN 2020, NYGC WILL HAVE SEQUENCED OVER 40,000 AUTISM GENOMES WITH SEVERAL PENDING PUBLICATIONS. IN 2019, NYGC ALSO RECEIVED SUPPLEMENTAL FUNDS TO SEQUENCE THE 2,504 PHASE 3 PANEL 1000 GENOMES SAMPLES TO HIGH COVERAGE, CREATING A LARGE HIGH QUALITY OPEN-SOURCE DATASET OF THESE DIVERSE REFERENCE SAMPLES FREELY AVAILABLE TO THE GENOMICS RESEARCH COMMUNITY.
EDUCATION	--------- AS PART OF NYGC'S EDUCATIONAL MISSION, IT HOSTED MANY SCIENTIFIC MEETINGS, WORKSHOPS, CONFERENCES AND LECTURES IN 2019. THE NYGC GENOME CENTER CANCER GROUP ORGANIZES THE NEW YORK CANCER GENOMICS RESEARCH NETWORK MEETINGS THAT ARE HELD ON THE FIRST TUESDAY OF EVERY MONTH DURING THE ACADEMIC YEAR, BRINGING TOGETHER LEADING RESEARCHERS AND CLINICIANS FROM NYGC MEMBER AND OTHER ACADEMIC AND COMMUNITY-BASED INSTITUTIONS. THE MEETINGS ARE INTENDED PRIMARILY FOR PRINCIPAL INVESTIGATORS AND THEIR TRAINEES IN THE NEW YORK REGION. IN 2019, FIVE NEW SCIENTIFIC WORKING GROUPS WERE ESTABLISHED AT THE NYGC: NEURODEGENERATIVE DISEASE; NEUROPSYCHIATRIC DISEASE, COMPUTATIONAL CANCER GENOMICS; POPULATION GENOMICS; AND ENABLING INNOVATION. THESE NEW GROUPS, ALONG WITH NYGC'S FOUNDING WORKING GROUP, THE GENOME CENTER CANCER GROUP, ARE FORUMS FOR DISCUSSING CURRENT RESEARCH ADVANCES, TECHNICAL AND CONCEPTUAL CHALLENGES TO FURTHER PROGRESS, AND THE ESTABLISHMENT OF JOINT PROJECTS AND FUNDING STRATEGIES. NYGC'S BIOINFORMATICS TEAM HELD ITS FIFTH SEQUENCING INFORMATICS WORKSHOP IN FALL 2019. THE WORKSHOP OFFERS A MIX OF LECTURES FROM EXPERTS IN THE FIELD AND HANDS-ON EXERCISES TO STUDENTS EARLY IN THEIR TRAINING OR CAREER WHO HAVE PROJECTS INVOLVING NEXT GENERATION SEQUENCING. NYGC HELD "EVENING TALKS," A LECTURE SERIES FOR THE GENERAL PUBLIC ON ADVANCES IN GENOMIC SCIENCE, SPONSORED BY THE NEW YORK CITY COMMUNITY TRUST-PYEWACKET FUND. THESE TALKS ARE DESIGNED TO MAKE THE LATEST GENOMIC RESEARCH DISCOVERIES MORE ACCESSIBLE AND UNDERSTANDABLE FOR THE GENERAL PUBLIC. THESE WELL-ATTENDED LECTURES (AVERAGING 150 GUESTS PER EVENT) FEATURE PANELS OF LEADING RESEARCHERS AND CLINICIANS FROM NYGC AND/OR MEMBER INSTITUTIONS. IN 2019, NYGC HELD TALKS ON RARE DISEASE GENOMICS, THE LATEST ADVANCES IN DNA ANALYSIS, AND SPACE GENOMICS. NYGC HOSTED "FIVE POINTS" LECTURES FOR THE SCIENTIFIC COMMUNITY, FEATURING LEADING RESEARCHERS FROM AROUND THE COUNTRY AND ABROAD. THESE LECTURES BRING LEADING SCIENTISTS TO NYGC FOR IN-DEPTH DISCUSSIONS OF THEIR WORK WITH RESEARCHERS, CLINICIANS, AND STUDENTS FROM NYGC, ITS MEMBER INSTITUTIONS, AND OTHERS IN THE SCIENTIFIC COMMUNITY. ORGANIZATION MEMBERS FORM 990, PART VI, SECTION A, LINE 6: AS OF DECEMBER 31, 2019, THE CENTER HAD A TOTAL OF 19 MEMBERS, CONSISTING OF 12 INSTITUTIONAL FOUNDING MEMBERS AND SEVEN ASSOCIATE MEMBERS. THE INSTITUTIONAL FOUNDING MEMBERS ARE THE FOLLOWING RECOGNIZED ACADEMIC, MEDICAL AND RESEARCH INSTITUTIONS: (1) COLD SPRING HARBOR LABORATORY, (2) CORNELL UNIVERSITY/WEILL CORNELL MEDICINE, (3) THE JACKSON LABORATORY, (4) MEMORIAL SLOAN-KETTERING CANCER CENTER, (5) ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, (6) NEW-YORK-PRESBYTERIAN HOSPITAL, (7) NEW YORK UNIVERSITY, SCHOOL OF MEDICINE, (8) NORTHWELL HEALTH, (9) THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, ON BEHALF OF STONY BROOK UNIVERSITY, (10) THE ROCKEFELLER UNIVERSITY, (11) THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, AND (12) ALBERT EINSTEIN COLLEGE OF MEDICINE. ASSOCIATE MEMBERS: (1) AMERICAN MUSEUM OF NATURAL HISTORY, (2) HOSPITAL FOR SPECIAL SURGERY, (3) THE NEW YORK STEM CELL FOUNDATION, (4) ROSWELL PARK CANCER INSTITUTE, (5) PRINCETON UNIVERSITY, (6) HACKENSACK MERIDIAN HEALTH, AND (7) GEORGETOWN LOMBARDI COMPREHENSIVE CANCER CENTER.
ORGANIZATION MEMBERS - DECISION MAKING	FORM 990, PART VI, SECTION A, LINE 7A & 7B: EACH INSTITUTIONAL FOUNDING MEMBER APPOINTS ONE REPRESENTATIVE TO SERVE ON NYGC'S BOARD OF DIRECTORS. THE BOARD OF DIRECTORS ALSO INCLUDES THE SCIENTIFIC DIRECTOR AND OTHER DESIGNATED DIRECTORS OR INDIVIDUALS APPOINTED BY THE BOARD. DECISIONS REQUIRING BOARD APPROVAL INCLUDE THE ADMISSION OF NEW MEMBERS, CHANGES TO THE MISSION, CERTIFICATE OF INCORPORATION, AND BYLAWS, APPOINTMENT OR REMOVAL OF THE CHAIRPERSON OF THE BOARD AND THE SCIENTIFIC DIRECTOR, AND ADOPTION OF CERTAIN POLICIES AND PROCEDURES. THE BOARD ALSO REVIEWS AND APPROVES THE ANNUAL OPERATING BUDGET. MANAGEMENT HAS THE ABILITY TO ENTER INTO BUSINESS ARRANGEMENTS AND CONTRACTS, INCLUDING FINANCING ARRANGEMENTS.
FORM 990 REVIEW	FORM 990, PART VI, SECTION B, LINE 11: THE FORM 990 IS PREPARED BY AN INDEPENDENT PUBLIC ACCOUNTING FIRM, UTILIZING INFORMATION PROVIDED BY MANAGEMENT. UPON RECEIPT OF THE DRAFT FORM 990, MANAGEMENT, INCLUDING THE DIRECTOR OF FINANCE; GENERAL COUNSEL; AND PRESIDENT & COO, REVIEW THE FORM. PRIOR TO FILING, MANAGEMENT PRESENTS THE FORM 990 TO THE AUDIT COMMITTEE OF THE BOARD FOR REVIEW AND COMMENT. ALSO PRIOR TO FILING, MANAGEMENT PROVIDES THE FORM 990 TO THE ENTIRE BOARD OF DIRECTORS.
CONFLICT OF INTEREST POLICY & REVIEW	FORM 990, PART VI, SECTION B, LINE 12C: NYGC REQUIRES ALL INTERESTED PERSONS (DEFINED AS BOARD MEMBERS, PRINCIPAL OFFICERS, OR MEMBERS OF A COMMITTEE TO WHICH THE BOARD HAS DELEGATED POWERS) TO DISCLOSE CONFLICTS OF INTEREST AS REQUIRED BY THE CONFLICT OF INTEREST POLICY. NYGC FOLLOWS A PROCEDURE FOR OBTAINING SUCH DISCLOSURES ANNUALLY. ANY POTENTIAL CONFLICTS OF INTEREST MUST BE REVIEWED BY THE BOARD. IF AN INTERESTED PERSON HAS A POTENTIAL CONFLICT OF INTEREST, HE OR SHE MAY MAKE A PRESENTATION AT THE BOARD OR COMMITTEE MEETING, BUT AFTER SUCH PRESENTATION, HE/SHE SHALL LEAVE THE MEETING DURING THE DISCUSSION OF, AND THE VOTE ON, THE TRANSACTION OR ARRANGEMENT THAT CREATES THE POTENTIAL CONFLICT OF INTEREST.
COMPENSATION REVIEW AND APPROVAL	FORM 990, PART VI, SECTION B, LINE 15: FOR THE ORGANIZATION'S TOP MANAGEMENT OFFICIAL, PLEASE REFER TO SCHEDULE J NARRATIVES FOR THE PROCESS OF DETERMINING COMPENSATION. IN LATE 2018 NYGC HIRED AN INDEPENDENT COMPENSATION CONSULTANT TO PERFORM AN EXECUTIVE TOTAL COMPENSATION STUDY OF SENIOR MANAGEMENT'S COMPENSATION. RESULTS OF THIS REVIEW WERE PROVIDED TO THE AD-HOC COMPENSATION COMMITTEE IN EARLY 2019 AND THE COMMITTEE DISCUSSED THEM. THE REVIEW SHOWED THAT THE COMPENSATION PAID TO ALL MEMBERS OF SENIOR MANAGEMENT (PRESIDENT AND COO, CHIEF BUSINESS OFFICER, SENIOR VICE PRESIDENT, FINANCE & ADMINISTRATION, SVP, GENOME TECHNOLOGIES, VICE PRESIDENT, DEVELOPMENT AND COMMUNICATIONS, VICE PRESIDENT & GENERAL COUNSEL, AND THE SCIENTIFIC DIRECTOR AND CEO) WAS REASONABLE. THE AD-HOC COMPENSATION COMMITTEE DISCUSSED SENIOR MANAGEMENT COMPENSATION IN EARLY 2019. THREE MEMBERS OF SENIOR MANAGEMENT RECEIVED MERIT INCREASES IN 2019 (PRESIDENT AND COO, VICE PRESIDENT & GENERAL COUNSEL, AND THE SCIENTIFIC DIRECTOR AND CEO), WHICH WERE APPROVED BY THE AD-HOC COMPENSATION COMMITTEE IN JANUARY 2019. WHILE THE SCIENTIFIC DIRECTOR & CEOS COMPENSATION IS SET BY AN UNRELATED ENTITY, THE AD-HOC COMPENSATION COMMITTEE COMMUNICATED WITH THE UNRELATED ENTITY TO APPROVE HIS MERIT INCREASE IN 2019. THE OTHER MEMBERS OF THE SENIOR MANAGEMENT TEAM DID NOT RECEIVE MERIT INCREASES IN 2019 AND THEIR COMPENSATION REMAIN UNCHANGED.
DOCUMENT DISCLOSURE	FORM 990, PART VI, SECTION C, LINE 19: NYGC'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST. COMPENSATION OF OFFICERS AND DIRECTORS FORM 990, PART VII, SECTION A IN 2019, THE SCIENTIFIC DIRECTOR & CEO, WAS EMPLOYED BY AN UNRELATED ENTITY AND LEASED TO NYGC TO DEVOTE 80% OF HIS TIME AND EFFORT TO SERVING AS NYGC'S SCIENTIFIC DIRECTOR AND CEO, AN OFFICER OF THE CORPORATION, AND AN ASSOCIATE MEMBER OF NYGC'S FACULTY, WITH RESPONSIBILITY FOR OVERSEEING NYGC'S RESEARCH PROGRAM AND FOR UNDERTAKING SUCH OTHER ACTIVITIES AS NYGC'S BOARD OF DIRECTORS REQUESTED FROM TIME TO TIME. THE SCIENTIFIC DIRECTOR & CEO DEVOTES 20% OF HIS TIME TO HIS DUTIES AT THE UNRELATED ENTITY, WHERE HE MAINTAINS A LABORATORY AND CONDUCTS INDEPENDENT, INVESTIGATOR-INITIATED RESEARCH PROJECTS.